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ABSTRACT  
 
Introduction. Microembolization during the carotid artery 
revascularization procedure may cause cerebral lesions. Elevated C-
Reactive Protein (hsCRP), Vascular endothelial growth factor (VEGF) and 
serum amyloid A protein (SAA) exert inflammatory activities thus 
promoting carotid plaque instability. Neuron specific enolase (NSE) is 
considered a marker of cerebral injury. Neoangiogenesis represents a 
crucial step in atherosclerosis, since neovessels density correlates with 
plaque destabilization. However their clinical significance on the outcome 
of revascularization is unknown.  This study aims to establish the 
correlation between palque vulnerabilty, embolization and histological or 
serological markers of inflammation and neoangiogenesis.  
Methods. Serum hsCRP, SAA, VEGF, NSE mRNA, PAPP-A mRNA 
levels were evaluated in patients with symptomatic carotid stenosis who 
underwent filter-protected CAS or CEA procedure. Cerebral embolization, 
presence of neurologicals symptoms, plaque neovascularization were 
evaluated testing imaging, serological and histological methods. Results 
were compared by Fisher’s, Student T test and Mann-Whitney U test.  
Results. Patients with hsCRP<5 mg/l, SAA<10mg/L and VEGF<500pg/ml 
had a mean PO of 21.5% versus 35.3% (p<0.05). In either group, embolic 
material captured by the filter was identified as atherosclerotic plaque 
fragments. Cerebral lesions increased significantly in all patients with 
hsCRP>5mg/l and SAA>10mg/l (16.5 vs 2.8 mean number, 3564.6 vs 
417.6 mm3 mean volume).  
Discussion. High hsCRP, SAA and VEGF levels are associated with 
significantly greater embolization during CAS and to the vulnerabiliy of the 
plaque. This data suggest CAS might not be indicated as a method of 
revascularization in this specific group of patients.  
Keywords: atherosclerosis, vasa vasorum, cerebral lesion, SAA 
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Overview of the PhD project and data obtained 
 
The main objective of our research project is the cellular and morphological 
characterization of carotid plaque vulnerability using different approaches; 
clinical analysis, immunohistochemical and molecular assays. The principal 
physiopathologic processes studied are inflammation, neoangiogenesis and 
calcification (osteogenic differentiation).  
Clinical study 
 
First we evaluated serological marker of cardiovascular disease in patients 
submitted to carotid artery stenting (CAS) or endarterectomy (CEA); 84 
patients with >70% carotid artery stenosis were preferentially submitted to 
CEA (50) or CAS (34). On CAS we showed a direct positive correlation 
between post procedural cerebral lesions, the quantity of thromboembolic 
material retrieved on the filter and pre-operatory serum levels of 
inflammation markers. Patients with high hsCRP (>5mg/l), SAA (>10 
mg/L) and VEGF (>500pg/ml) are associated with significantly greater 
embolization during CAS procedure and particularly in dishomogenous 
plaque. Volume and number of total cerebral lesions post procedural 
increased significantly in all patients having high hsCRP and SAA values. 
These data suggest that CAS might not be indicated in this specific group of 
patients with plaque prone to rupture. Secondly we compared different 
histological parameters of plaque vulnerability with the Contrast-enhanced 
Ultrasonography. An increase of dB-E was associated significantly with 
thinner fibrous cap (TFC <200 um, dB-E: 5.96 vs 3), greater inflammatory 
infiltrate (7.4 vs 3.2) and greater microvessels density (5.5 vs 2.5). We 
observed that either in symptomatic patients or in presence of pre-operative 
cerebral ipsilateral embolic lesions, dB-E values increased significantly 
(respectively 7.4 vs 3.5 and 5.96 vs 3.0) (3). In addition we observed that 
patients having neurological symptoms pre-operatively and vulnerable 
plaque had also high VEGF and hsCRP serum levels compared with 
patients with non vulnerable. There was an inverse linear correlation 
between VEGF serum concentration and fibrous cap thickness. All patients 
presented an increase of 32% of neuronal specific enolase mRNA level 
expression after the CAS procedure compared to patients submitted to CEA 
procedure.  
 
Study on vasculogenic niche  
Another aspects of the research project is the vasa vasorum (VV) 
neovasculogenic potential and involvement in atherosclerosis. We studied 
Nestin, WT1, dPAPP-A and SAA4 expression in vasa vasorum in human 
normal arteries (n°20). We saw that Nestin and WT1 in adult VV are 
expressed in adult VV, especially in VV <50 µm diameter and gathered in 
“hot spots”. The cytoplasmic colocalization of WT1 and nestin straightens 
the role of WT1 as a post-transcriptional activator of nestin protein. In our 
series WT1 was mainly cytoplasmic in the larger vessels, while nuclear 
expression increased in the smaller vessels (“second-order” VV). The 
nuclear localization of WT1 could express an increasing transcriptional 
activity in progenitor-committed Nestin-positive cells. We want to compare 
WT1/Nestin mRNA and protein hot-spots sub-cellular localization in 
normal arteries versus pathological arteries to assess a correlation with 
neovascularization during atherogenesis. The “hot spot” could therefore 
represent a valid model for the vasculogenic niche and the main source for 
neovasculogenesis during atherosclerosis. We are now performing the same 
analysis in atheroma lesions. We saw that dPAPP-A and SAA4 are specific 
histological and serological markers of atheromasic lesions presence. We 
also studied (data not presented) a case of pulmonary artery undifferentiated 
intimal sarcoma that expresses previously unreported markers; RUNX-1, 
Nestin, WT1 and CD44, commonly seen in different stages of the vascular 
differentiation hierarchy. These findings raise the question whether this 
neoplasm derives from a vessel wall-resident stem cell, like the 
hemangioblast or an embryonic-like stem cell.  
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INTRODUCTION
1
Introduction
INTRODUCTION
Atherosclerosis
In 1628 William Harvey, St. Bartholomew's Hospital, London, describes the
function of the heart, arteries and veins. It is considered to be one of the
greatest advances in medicine. Between 1783 and 1793 Edward Jenner, a
British country physician who created the smallpox vaccine, while doing an
autopsy accidentally discovered coronary arteries disease. He was probably
the first to associate angina pectoris with hardening of the arteries (Fig 1).
 
 
Figure 1: Edward Jenner and a stomach flattened and injected with wax to
show the veins and arteries.
Highlights of the introduction
Nowadays, in occidental countries cardiovascular events,such as stroke, are
the leading causes of death, thus the priority of primary and secondary
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prevention (Rosamond et al., 2007). Even if selected patients with acute
ischemic stroke are treated with promising experimental therapies, such as
tissue plasminogen activator, the best approach to reduce stroke remains
still prevention. An early diagnosis allows individuals at higher risk or
prone to stroke to be identified and targeted for specific therapies or
interventions (Goldstein et al., 2001). The presence of atherosclerotic
lesions at the carotid bifurcation and the presence of ischemic cerebral
lesions are the main factors leading to cardiovascular events. In fact, the
presence of recent focal neurological symptoms ipsilateral to a carotid
stenosis is a powerful predictor of ‘high risk’ carotid atherosclerosis.
Especially, the risk of major events such as death or stroke, is further
increased in patients presenting vulnerable plaque (Wang et al., 2010). The
degree of stenosis is still the gold standard to assess stroke risk and
subsequent indication to revascularization (R Rosamond et al., 2007). In
symptomatic or asymptomatic patients with a stenosis greater than 60%,
carotid endoarterectomy procedure (CEA) results respectively in a 56% and
34.5% reduction of the development of major events, thus proving the
efficacy of the CEA intervention (ACAS 1991). However waiting time
between diagnosis and CEA intervention can result in an interval stroke rate
of 9%-15%. The aim of the early intervention is to avoid embolization
caused by a vulnerable lesion at the carotid district, nevertheless there is a
big issue to recognize “young” vulnerable plaque non-invasively before an
acute clinical event occurs. (Setacci, et al., 2008). Different studies estimate
the individual risk of stroke such as the Framingham risk score or the
ABCD2 score system. The prognostic value of all these score systems
improves if completed with clinical information, vascular imaging data and
brain imaging data of patients. (A. Bhatt et al., 2011). Cerebro-ischemic
symptoms, as transient ischemic attacks or amaurosis fugax, increased the
risk of major events such as death or stroke (Liapis et al., 2001). In a
magnetic resonance imaging prospective assessment study, it has been
3
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shown, that the occurrence of cerebrovascular events in asymptomatic
patients is associated with the characteristics of carotid plaque; thinned or
ruptured fibrous caps, intraplaque hemorrhage, larger lipid-rich necrotic
cores and larger maximum wall thickness. (Takaya 2006 ). 
Stroke risk prediction based only on conventional risk factors is not enough;
hence research is oriented on predictive biological biomarkers. Previous
studies  demonstrated the correlation between serological and structural
markers of inflammation and neoangiogenesis related to the risk of
cardiovascular events in the coronary district (Ferri et al., 2006). Thus
biomarkers knowledge is necessary to allow primary prevention of coronary
events (Muller et al., 2006). However there is yet no standard value for
biomarkers able to identify a vulnerable plaque in the carotid district. 
Evaluation of the silent atheroma non-invasively is only possible through
recent imaging approaches and computed analysis such as pixel density
analysis and elastography at Duplex examination, local temperature probe
(Setacci, et al., 2008); these techniques allow to evaluate echostructural
alterations, such as ulcers, typical of vulnerable plaque but not molecular
composition. Thus, in addition to structural plaque analysis and
inflammation protein, particular attention is given to molecular pathway
involved in the atherosclerotic lesions development. 
Studies related to the discovery of novel biomarkers signature involved in
plaque destabilization and stroke are of fundamental importance .
Carotid plaque: pathogenesis
Atherosclerosis is characterized by intimal lesions, the atheromas, which
are protrusions within the vascular lumen that can determine alterations in
the normal blood flow and direct damage to the vessel structure. At first,
4
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these lesions present a focal distribution in the artery; however, they rapidly
begin to increase in number as the disease advances, until affecting the
whole circumference of the vessel walls that are more severely damaged
(Fig 2). 
The structure of the basic lesion consists in a plaque localised in the intima
presenting a central lipid core ( cholesterol and its esters) covered by a
fibrous cap. 
 
 
Figure 2: Structure of a blood vessel (right: healthy type, left: atheromasic
vessels)
Atherosclerotic plaques are mainly composed of cellular elements: smooth-
muscle cells, macrophages and leukocytes, connective tissue of
extracellular matrix – collagen, elastic fibres and proteoglycans – and intra-
and extracellular lipid deposits. (Fig 3). The relative proportion of these
components varies depending on the different plaques, which results in a
wide spectrum of lesions with different degrees of instability. The
overlaying fibrous cap is composed of smooth-muscle cells, few leukocytes
and relatively dense connective tissue. The cellular area which is below and
5
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adjacent to the fibrous cap – the “shoulder” of the fibrous cap – is
composed of macrophages, smooth-muscle cells and T lymphocytes. The
deep necrotic core presents a disorganised mass of lipid material, which is
composed of cholesterol crystals, cellular debris, thrombi undergoing
organization and other plasma proteins. Lipids are mainly composed of
cholesterol and its esters. There are cells that have phagocytized this lipid
material: they are called “foam cells” and they are, in particular circulating
monocytes activated in macrophages, and activated smooth-muscle cells.
Finally, especially at the periphery of the lesions, frequent aspects of
neovascularization can be detected and they are represented by the
proliferation of blood vessels that can be more or less mature. The
variations in the histological characteristics of the plaques depend on the
number of smooth-muscle cells and macrophages, the amount of collagen
and other extracellular components, besides the lipid contents (Cotran et al.,
VI Ed)
The pathogenic development of these lesions is still unclear; the
endothelium is believed to play a fundamental role in the initial
development of the plaque. The most widely accepted hypothesis is that
what triggers this process is a reaction to the damage of the intima.
Therefore, atherosclerosis would represent an inflammatory response of the
vessel wall (Ross et al., 1993). The element that characterizes the primary
lesions is the presence of an endothelium that is not morphologically
damaged yet. This has led to consider that the most important factor in
development of the disease is a cellular dysfunction and activation, together
with an increase in the endothelial permeability, rather than a direct damage.
This process manifests itself with an increased leukocyte and monocyte
adhesion, which is highlighted by alterations in the expression of the
endothelial adhesion molecules ICAM-1 and VCAM-1 (InterCellular
Adhesion Molecule 1, Vascular Cell Adhesion Molecole 1) (O'Brien et al.,
1996; Cybulsky et al., 1991; Gimbrone et al., 1997).
6
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Figure 3: Development and progression of atheromasic lesions (Fortunato
et al, 2007).
The main causes of the endothelial dysfunction and damage are the
hemodynamic changes that occur in some specific points of the circulatory
tree – major branch points and bifurcations – and the harmful effects of
hypercholesterolemia. 
Effects of hemodynamics on vascular cells. 
In support of the role of the blood flow, and of its changing from laminar to
turbulent with a loss of tangential force – and, therefore, a low “shear
stress” – it is relevant to consider the location of the plaques, which can be
more frequently found at the ostial area or at the bifurcations.
The blood flow undergoing these changes, with variable levels of parietal
stress, is believed to cause the endothelial dysfunctions and thus predispose
the development of these lesions in these predictable locations (Fig 4).
Cyclic strain has been shown to stimulate expression of cellular adhesion
molecules such as ICAM-1 and intracellular second messenger systems
such as the adenylate cyclase-cAMP, diacylglycerol-IP3, and protein kinase
7
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C pathways (Pradhan et al., 2004).
 
Figure 4: Hemodynamic forces. A) Severe stenosis proximal left internal
carotid artery as seen in 3D (Rochester Medical Center) B) Endothelial cells
are subjected to both a tangential, parallel force (shear stress) as well as a
circumferential, perpendicular force (cyclic strain). (Pradhan et al., 2004).
 
 
This causes the activation of many pro-inflammatory and pro-atherogenic
genes, thereby the production of cytokines, adhesion molecules and
coagulation proteins, which produce an increase in the endothelial
permeability, the cellular turnover and the cellular endocytosis of the LDL
that is present in this area.
Hypercholesterolemia. 
Hypercholesterolemia can trigger the development of plaque, due to a
higher deposition of cholesterol in the subintimal area. Moreover,
hyperlipidemia itself determines an endothelial dysfunction owing a greater
production of superoxide dismutase and other free radicals of oxygen that
deactivate nitric oxide, which is the main relaxing factor in arteries. The
oxidative modifications induced by free radicals, and produced by
8
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macrophages and endothelial cells, lead to the formation of oxidized LDL
molecules, which in turn contribute to the formation of lesions in different
ways: 
Oxidized LDL:
1. can be easily phagocytized by macrophages, resulting in the formation of
foam cells,
2. are chemotactic for circulating monocytes,
3. increase the adhesion of the monocytes especially by inducing
endothelial adhesion molecules, 
4. inhibit the viability of the macrophages that are already in the lesion by
facilitating the recruitment and the survival of the macrophages in the
plaque, 
5. stimulate the release of grow factors and cytokines,
6. are cytotoxic to the endothelial cells and the smooth-muscle cells,
7. are immunogenic, as they induce the production of antibodies against the
oxidized lipoproteins.
 
The idea that hyperlipidemia leads to the formation of lesions by means of
the oxidative stress on the endothelium is proven by clinical and
experimental studies which show how antioxidant proteins and medications
that reduce oxidation have a protective effect on atherosclerosis. Moreover,
the decrease in cholesterol and the antioxidant therapy improve the
endothelial function (Steinberg, 1997)
During the genesis of the plaque, monocytes subsequently adhere to the
activated endothelial surface, thanks to the adhesion molecules, and through
these cells they migrate to the subendothelial area. Here they differentiate
into macrophages and phagocytize the oxidized LDL molecules, thus
9
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becoming foam cells. Macrophages play a multifactorial role in the
progression of atherosclerosis thanks to the secretion of proteins such as the
interleukins (IL-1) and the tumour growth factor (TNF), which increase the
adhesion of the leukocytes. Furthermore, macrophages produce radicals of
oxygen, which cause the oxidation of the LDL molecules in the lesion, and
elaborate growth factors that can contribute to the proliferation of the
smooth-muscle cells. Prematurely during the development of the lesion, the
smooth-muscle cells migrate to the intima, where they proliferate and
determine the deposition of extracellular material, thus facilitating the
enhancement of the plaque (Ridker et al., 2002).
During the early stages of atherogenesis, the intimal plaque is composed of
an aggregation of foam cells, some of which may die and release
extracellular lipids and cellular debris, which surround the muscle cells. The
adipose cellular atheroma gradually changes, as a consequence of the
deposition of collagen and proteoglycans. The connective tissue,
particularly abundant in the intimal area, produces the fibrous cap, which
then develops in the mature fibroatheroma. Some of these lesions
subsequently undergo further modifications:
A. accumulate of larger amount of connective tissue, thus becoming fibrous
plaques. 
B. calcification deposits. 
C. develop a central core that is rich in lipids and foam cells, which increase
the potential risk of developing serious complications (Ross et al., 1993).
10
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The fibrous cap
The fibrous cap is the outer fibrous part that covers the atherosclerotic
plaque. It is the structure that separates the blood flow from the necrotic
core of the lesion, therefore it is very important for the stability of the
plaque. If there are lesions on its surface, circulating elements – platelets
and coagulation factors – can come into contact with the inner elements of
the plaque, thus causing the formation of thrombi (Fig 3).
The fibrous cap originates from the secretory activity of the smooth-muscle
cells. These cells migrate from the media to the sub-endothelial area –
during the formation of the plaque – where they produce collagen, elastic
fibres and proteoglycans, in order to limit the expansion of the
inflammatory process of the plaque towards the vascular lumen (Ross et al.,
1993; O'Brien et al., 1996; Cybulsky et al., 1991; Gimbrone et al., 1997;
Mauriello et al., 2010)
Therefore, the presence of a thin-fibrous cap represents a condition of
unstable plaque prone to rupture. The development of a thin-fibrous cap is
determined by a series of phenomena: 
1. activation of the leukocytes inside the plaque and production of
metalloproteinases,
2. degradation of collagen and proteoglycans, which are produced by the
smooth-muscle cells, 
3. release of cytokines that can reduce the activity of the smooth-muscle
cells.34
Histological tests have highlighted that the thin-fibrous cap is associated
with higher concentrations of macrophages in the subendothelial area. The
11
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thin-fibrous cap (<65 µm) is a condition of instability of the plaque, because
it may cause ruptures on its surface, independently from the size of the
necrotic core.
In general, in the areas that present lesions of the fibrous cap that do not
determine more severe clinical manifestations, the healing of the ulcerated
surface is not complete. These areas present a weaker resistance that can
subsequently determine other fractures on the surface, which can be
associated with more severe clinical manifestations. This explains the
typical manifestations of the carotid plaque. As a premonitory sign we can
consider transient ischemic attacks (TIA), which are the epiphenomenon of
a microfracture on the surface of the atherosclerotic lesion; in the following
days, this may result in a major ischemic event (stroke), due to another
rupture of the plaque that had not completely healed (Redgrave et al., 2006;
Virmani et al., 2003; Virmani et al., 2006).
Instrumental evaluations. In the ultrasound study, the morphology of the
surface of the plaque represents an additional element in the evaluation of
the risk associated with a carotid lesion, besides the analysis of the degree
of stenosis. Therefore, the identification of alterations on the surface of the
plaque, such as the ulcerative lesions (which are identified as introflexions
of the surface of the plaque of at least 2 mm per 2 mm of length), is very
important in the overall evaluation of the patient, as it allows to identify an
additional risk of ischemic events (Fig 5). There are other methods of
imaging such as the Computerized Tomography (CT) or the Magnetic
Resonance (MR), which allow to identify the structural alterations and the
risk of cerebral events due to the presence of a particularly thin-fibrous cap.
However, in the clinical practice they are used less than the ultrasound scan
(Lovett et al., 2004; Wasserman 2008; Takaya et al., 2006).
12
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Figure 5: Ulcerated plaque on the surface of the fibrous cap (arrow),
identified by means of an ultrasound evaluation. The presence of lesions in
the structure of the carotid plaque represents a condition of structural
instability and, therefore, of a higher risk of cerebrovascular events
The alterations on the surface of the plaque or the identification of a thin-
fibrous cap represent a condition of instability of the plaque and a higher
cerebrovascular risk; however, their role is marginal in the decision-making
process for the surgical treatment of the carotid lesions. Indeed, the data of
most of the clinical trials, from which the current indications originate, refer
above all to the evaluation of the degree of stenosis and to the
symptomatology that is associated with it. 
Plaque classification
The classification of atherosclerotic lesions was initially carried out by
macroscopic observation, using descriptive terms such as "Lipid streak" or
13
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atheromatous plaque, fibrous or broken. The terminology varied from study
to study so the correlation of data was impossible. In 1994-1995, the
American Heart Association (AHA) has established criteria by which
plaques are classified according to cellular content and structure, analysing
the area of major lesion (Stary et al., 1995) (Table 1a). It is important to
differentiate;
– young stable plaque with a low extracellular lipid content, less
dangerous (types I–III)
– unstable plaque, more dangerous types including plaque with a high
extracellular lipid content (types IV and Va), more prone to rupture
and acute thrombosis (Richardson et al 1989; Cheng 1993), 
– and older calcified and fibrotic plaque (types Vb and Vc), which are
dangerous because of their high degree of stenosis and the risk of
rupture (Table 1a, b).
Table 1a: AHA classification
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Table 1b: This second table above is a summary of the crucial definitions related
to the vulnerable plaque (Schaar et al., 2004).
The calcification 
The calcification at the level of the arteries is a process that is not clear yet
and can appear both at the level of the media and at the level of the intima.
Media. The involvement of the media, which is defined as Monckeberg’s
calcific sclerosis, is a process that begins in areas that are not generally
involved in atherosclerotic manifestations, such as the distal vessels of the
limbs, the visceral vessels and the thyroid vessels. The calcification is
associated with pathologies characterised by ionic alterations: metabolic
dysfunctions, electrolyte disorders, diabetes and chronic kidney failure. The
calcification can also be determined by alterations of the nerve stimuli and
neuropathies. Another possible cause is the lumbar sympathectomy, after
which the area of the sympathectomy shows an increased development of
calcifications of the media in the vessels of the ipsilateral foot (88% in 2
years) compared to the contralateral foot (18%). 
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Intima. The most common condition is the intimal calcification that
develops at the level of the atherosclerotic lesions. The most widely
accepted hypotheses associate the inflammation in the plaque with the
deposition of calcium crystals (besides the effect caused by alterations in
the metabolism of phosphorus and calcium). The phlogosis at the level of
the atherosclerotic lesion is associated with the release of cytokines, which
cause the production of molecules that stimulate the formation of calcified
nodules. The Bone Morphogenetic Protein 2 (BMP2), which is secreted by
the smooth-muscle cells, plays a fundamental role in this process. The
stimuli inside the plaque can be very weak – thus determining
microcalcifications – or they can be particularly intense, thus causing a
progressive differentiation of the smooth-muscle cells into cells with an
osteoblastic/ osteoclastic activity and the formation of bone matrix or even
bone tissue. In the atherosclerotic plaques, calcium initially develops in
nodules that are at a basal level and, subsequently in microcrystals in the
whole plaque (Doherty et al., 2004; Abedin et al., 2004: Demer et al., 2003).
At the level of the vessels, the identification of calcifications can be an
indicator of atherosclerosis. In the coronary arteries, calcium is located only
in the atherosclerotic plaques: for this reason, methods such as the TC have
been introduced for the non-invasive evaluation of these lesions (Calcium
Score). At the level of the carotid stenoses, as the ultrasound scan is the
most used method of investigation to easily identify the presence of a
plaque, the role of the calcification as an indicator of atherosclerosis is not
considered. On the contrary, the presence of calcific deposits in the carotid
is an indirect indicator of the instability of the plaque. Indeed, the
histological evaluation of the carotid plaques has highlighted in many
studies that, in general, the calcified plaques can be found in asymptomatic
patients, whereas calcifications are scarce or inexistent in patients who have
had a neurological symptomatology and, thus, with unstable lesions.
Afterwards, analyses on anatomopathological reports have confirmed that
16
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the calcification inside the carotid plaque is associated with a thicker
fibrous cap and a less significant development of the lipid core, which both
determine the stability of the plaque (Huang et al., 2001).
In the ultrasound evaluation, the presence of calcifications is identified
thanks to the presence of a marked hyperechogenicity, which can also
determine the development of an acoustic shadowing due to the total
reflection of the ultrasound waves. This makes the evaluation of the
atheromatous lesion possible; therefore, in these lesions, the evaluation of
the flow modification after the acoustic shadow is fundamental for the
identification and evaluation of the degree of stenosis.
Another type of calcification is “a plaque with a calcified nodule” which is
a heavily calcified plaque with the loss and/or dysfunction of endothelial
cells over a calcified nodule. This is the least common of the three causes of
thrombosis described here (Virmani et al., 2000, Table 1b).
Calcification triggers' mechanism in arteries is still unknow. The
identification of a calcified carotid lesion is interesting for the indication of
a possible surgical treatment.
The lipid core
 
The lipid core of the carotid plaque is the most interesting element for it
represents the main factor determining the stenosis and, consequently, the
cerebral ischemic risk. The core is mainly composed of LDL molecules that
cross the vascular endothelial barrier from the blood flow and accumulate in
the intima. The macrophages are recruited and activated by the
subendothelial deposit and differentiate into foam cells. These cells release
oxidizing substances, which determine the formation of the oxidized LDL
molecules, which have a chemotactic role as they stimulate the evolution of
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the atheromatous lesion. The serum concentrations of cholesterol, with high
values of LDL and low values of HDL, are fundamental for the
development of the carotid plaque and are related to a larger accumulation
of lipids inside the plaque. The presence of an abundant lipid component
inside the carotid plaque increases plaque instability, for different reasons
(Ross et al., 1993)
1. greater fragility with possible events of internal haemorrhage,
2. increased phlogistic component, 
3. presence of a thin-fibrous cap,
4. strong stimulus to the aggregation of platelets in case of lesions. 
 
As a consequence, the methods for the identification of these lesions rich in
lipids are very important. 
Hypercholesterolemia. The evaluation of the serum concentrations of
cholesterol is the most helpful element: the study ACST (Asymptomatic
Carotid Surgery Trial) highlights how patients with a carotid stenosis over
70% and values of blood cholesterol over 250 mg/dl present a significantly
higher risk of ischemic events than the group of patients with lower
cholesterol serum levels. The endarterectomy treatment of these lesions
determines a total reduction of the risk of events, in a 5-year period, by
11,7% in patients with high levels of cholesterol and by 4,6% in patients
with lower levels (MRC (ACST) 2004).
Instrumental evaluation. The evaluation of the carotid plaques by means of
imaging methods helps to identify the internal component of the core.
Today the B-Mode ultrasound evaluation is used for the internal description
of the plaque, which is defined as hypoechogenic if it appears structurally
darker than the adventitial component. This is due to the fact that the lipid
core does not determine the reflection of the ultrasound waves and,
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therefore, appears as dark. However, the direct evaluation does not allow an
objectification of the result; for this reason, it is defined as “dependent
operator” and considered as liable to individual variations. The analysis of
the structure of the plaque by means of the Grey Scale Measurement (GSM)
represents a more objective method. This method takes into account the
average variation of the grey scale in the area of the plaque, returning a
numeric result, which, thus, is not subjective. (Fig. 6) 
Figure 6: evaluation of the Grey Scale Measurement (GSM). In the area of
the plaque, the average of the grey scale is calculated and a numeric value
indicating the degree of hypoechogenicity is produced.
Evaluations by means of this method have highlighted that symptomatic
plaques generally have lower values of GSM (<50), whereas asymptomatic
plaques have higher values, which is an indicator of a structure that is more
stable and less prone to possible complications. Moreover, long-term
evaluations have highlighted how plaques with low GSM levels can
determine ischemic events (Kern et al., 2004; Biasi et al., 1999).
As already mentioned before, also methods such as TC and MR can be used
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to analyse the structure of the core, which confirms that lesions that are
structurally richer in lipid component present higher long-term
cerebrovascualr risks (Takaya et al., 2006; Cappendijk et al., 2008).
Pharmacological therapies. The use of therapies with pharmaceuticals that
can determine a reduction of the blood concentrations of lipids and
cholesterol, such as the inhibitors of the HMG-CoA Reductase (statins), has
resulted in a reduction of the cerebrovascular risks by both having an effect
on the lipid levels and reducing the phlogistic condition that characterises
atherosclerosis. It has been demonstrated that high doses of statins are
effective for the stabilization of the carotid plaque. Ultrasound evaluations
in patients with carotid stenosis between 40% and 60%, and receiving
Atorvastatin therapy 80 mg/die (for 12 months), have highlighted a
significant ultrasound stabilization of the plaque (with an increase of the
GSM from 66 to 100) compared to patients receiving low doses of the same
medication (GSM from 64 to 85) (Kadoglou et al., 2010).
Other studies have highlighted how the statin therapy can determine a
significant reduction in the concentrations of macrophages and
inflammation inside the carotid plaque (Tang et al., 2009).
Statins have resulted as being helpful in the treatment of the carotid
stenoses, because they reduce the lipid component of the core and stabilize
the plaque. However, in presence of lesions that are hemodynamically
significant, the effectiveness of the statins in preventing cerebrovascular
events has not been demonstrated yet (Treasure et al.,1995; Anderson et al.,
1995).
Biomarkers and vulnerable plaque
Previously, atherosclerosis was thought primarily as a "plumbing" problem.
The degree of stenosis on an angiogram, symptoms and signs of ischemia
provided the main tools to assess atherosclerosis. In the last decades, studies
on the pathogenesis of the disease have grown fast (Libby et al. 2005). The
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understanding of the pathophysiology of this disease has now entered a new
era based on understanding of the biology and a critical reappraisal of the
pathobiology of atherothrombosis (Hansson et al. 2006).
Biomarker are measurable and quantifiable biological parameter such as
protein, enzyme or hormone concentration, gene phenotype distribution in a
population. Biomarker’s evaluation is a useful indicator of a normal
biological process, pathogenic process, or the pharmacologic response to a
therapy. The properties of a biomarker depend on their use. Currently the
techniques available for biomarker development are genomics, proteomics,
metabolomics, pharmacogenetics, integratomics, bioinformatics and
molecular imaging technologies. Several categories of biomarker have been
described that are pertinent to cancer, namely screening, diagnostic,
prognostic, predictive, pharmacological, surrogate response and safety
biomarker. Biomarker assays need to be carefully validated and be robust,
reliable and reproducible when applied in clinical contexts (Murukesh et al.,
2010). Biomarker's application in cardiovascular disease risk assessment is
multiple: screening diagnosis, prognostication, prediction of disease
recurrence, and therapeutic monitoring. (Vasan, 2006)
For the prediction of atherothrombotic events, markers of inflammation,
fibrinolysis, oxidative stress, and altered lipid metabolism are currently in
discussion. Also new emerging biomarker are in consideration, for example
MPO, PAPP-A, neuron-specific enolase (NSE) represented in the table 4
(Hermus et al. 2010).
During plaque formation different pathological processes involved in the
progression of atheromasic lesions are associated with plaque vulnerability,
21
Introduction
such as inflammation, neoangiogenesis, lipid accumulation, apoptosis,
proteolysis and thrombosis. Also morphological characteristics are related
with plaque instability such as ulceration Fig 7 (Hermus L et al. 2010).
Biomarker's studies are based on the concept, that a vulnerable plaque
contains predictive information for future cardiovascular events, also in
other areas of the vascular tree (Lammeren et al., 2011). Results are
promising and plaque markers can be used to develop imaging methods to
identify patients at risk and to monitor treatment effect. Plaque biomarker
studies use the concept of vulnerable plaque to favour the prediction of
vascular patients.
Vulnerable plaque
Vulnerable plaque are characterized by a large lipid core, a thin fibrous cap,
a rich infiltrate of macrophagic inflammatory cells and scarce smooth
muscle cells. Atherosclerotic plaque prone to rupture have specific
structural, cellular, and molecular characteristic listed in Table 2 and
illustrated in figure 7. The presence of a thin fibrous cap overlaying a large
lipid core increase at high risk for rupture. Plaque rupture usually leads to
various degrees of thrombus formation. Thrombosis may result in unstable
angina, myocardial infarction, or sudden death, particularly if collateral
flow is inadequate.
Early identification of high-risk plaque is critical, but vulnerable plaque is
not detectable with the current diagnostic methods. If this plaque could be
detected a major advance in healthcare would be achieved.  Identification
methods available are thermography, spectroscopy, radioisotope
scintigraphy, more recently optical coherence tomography and ultrasound
imaging. Nowadays the concept of vulnerable plaque is evolving towards
patient vulnerability. Vulnerable plaque are not the only cause of
symptomatic events, others parameters are involved, i.e. vulnerable blood
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(prone to thrombosis) plays an important role in the outcome. Therefore, the
term "vulnerable patient" is more appropriate and is now proposed for the
identification of subjects with high likelihood of developing cardiac events
in the near future (Naghavi et al., 2003).
Figure 7: Overview of a stable atherosclerotic plaque and an unstable
atherosclerotic plaque (Lammeren et al., 2011).
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Features of Rupture-Prone Plaque
Structural
Large lipid-rich core
Thin fibrous cap 
Reduced collagen content 
Cellular 
Local chronic inflammation
Increased macrophage density and activity
T-lymphocyte accumulation near sites of rupture
Increased neovascularization
Reduced density of smooth-muscle cells
Increased number and activity of mast cells
Expression of markers of inflammatory activation 
Molecular
Increased tissue-factor expression
Matrix metalloproteinase secretion
Table 2: Features of plaque prone to rupture 
Traditional biomarker
Conventionally, biomarker are identified based on large epidemiologic
studies demonstrating the significative statistical association between a
phenotype and the studied biomarker. Markers for risk are considered a
biochemical signature that correlates with the increased risk of the disease
development as determined by clinical and epidemiological studies. C
reactive protein (CRP) has emerged as an independent predictor of an
incident cardiovascular event in more than 15 large prospective studies,
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adding a prognostic value to that conveyed by the Framingham Risk Score.
In addition the lack of correlation between LDL-cholesterol and CRP
allowed the identification of a subgroup of patients with increased incidence
of coronary artery disease but a normal lipid profile (Koenig et al., 2005,
Ridker et al., 2002). Some of the most common markers of cardiovascular
disease are listed in table 3. 
RISK Total
Cholesterol
mg/dl
LDL 
mg/dl
HDL
mg/dl
TG 
mg/dl
Omocistein
umol/l
HsCRP 
mg/l
BNP 
pg/ml
LOW <200 <130 >60 >200 2 -15 <1 <100
MODERATE 200-240 130-160 40-60 200 - 400 31-100 1 - 3
HIGH >240 >160 <40 >400 >100 >3 >100
Cardiovascular risk
Hyperlipidemia => increased risk
Cardiovasc
ular risk
Inflammati
on
disease
Cardiovasc
ular risk
Table 3: Markers of dyslipidemia and new marker (omocistein, hsCRP and
BNP).
Emerging biomarker
Serum biomarker representing inflammatory activity in vulnerable carotid
plaque may be used to identify high-risk patients for cerebral ischemic
events. In a study on 100 patients, the relationship between 4 biomarkers-
Neopterin, PTX3, sCD163, sTREM-1- and neurological symptoms,
presence of coronary (CAD) and peripheral (PAD) artery disease was
analysed. Serum neopterin and sTREM-1 levels may be related to the
presence of atherosclerotic disease, but not to carotid plaque vulnerability
(Hermus et al.,. 2011).
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Recent analysis of inflammatory markers, including hs-CRP, interleukins 6,
10 and 18, soluble CD40 ligand, P- and E-selectin, NT-proBNP, fibrinogen
and cystatin C, in patients with acute coronary syndrome showed that all
markers by themselves offer only limited incremental information to
clinical risk scores. However, a combination of fibrinogen and NT-proBNP
contained predictive information in addition to clinical parameters
(Lammeren et al .,2011).
Leukocyte telomere length is also associated with the presence of
atherosclerotic carotid plaque but is not a proxy for local plaque telomere
length. Plaque telomere length is related to plaque characteristics and
development of restenosis following endarterectomy (Huzen et al., 2011).
Biomarker; applications always changing.
Biomarker are promising but also have limitations due to their instability or
involvement in different pathways; as an example the role of homocysteine is
very controversial. In 1969 Kilmer McCully reported an association
between increased homocysteine and premature cardiovascular disease,
since then many studies and trials demonstrated that homocysteine is an
independent risk factor for cardiovascular disease (McCully et al., 1969;
Ueland 2008). But, forty years later, this hypothesis has not been
conclusively confirmed or refused. 
In fact, in the NORVIT trial, enrolling 3,749 subjects who had a recent
myocardial infarction there was a trend towards a worse outcome in the
group given the combination of folic acid, vitamin B6, and vitamin B12
(Bønaa et al., 2006).
In the HOPE 2 trial (The Heart Outcomes Prevention Evaluation) that also
targeted patients at risk of vascular events, 5,522 subjects were randomized
to placebo or the combination of folic acid, vitamin B6, and vitamin B12.
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Over a 5-year follow-up period, the homocysteine-lowering therapy did not
significantly reduce the composite primary end point of death from
cardiovascular causes, myocardial infarction, and stroke. A recently
published study from Norway in 3,096 subjects undergoing coronary
angiography examined the effect of placebo, vitamin B6 alone, folic acid
and vitamin B12 administered together, or the combination of folic acid and
vitamins B6 and B12. There was no effect of any vitamin therapy on total
mortality or cardiovascular events (Ebbing et al., 2008).
So modifying an established risk factor does not always contribute to
decrease the risk of cardiovascular disease. Another example is a trial that
determines whether obese patients benefitted from treatment with
rimonabant in terms of progression of carotid atherosclerosis. There was no
difference in atherosclerosis progression between patients receiving
rimonabant for 30 months and those receiving placebo. This finding
suggests that a 5% loss of body weight over a 30-month period with
rimonabant is not sufficient to modify the progression of atherosclerosis in
the carotid artery in obese patients with metabolic syndrome (O'Leary et al.,
2011).
Still, promising studies of accurate and inexpensive markers for
cardiovascular risk assessment are useful in improving the selection of
subjects for prevention therapy. Identifying a biomarker can also lead to a
preventive or curative therapy aimed to decrease its level of expression.
A promising example for the application of a biomarker is a study on the
effects of Varespladib methyl on inflammation and cardiovascular risk. As
mentioned above, secretory phospholipase A2 (sPLA2) is a family of pro-
atherogenic enzymes involved in lipoprotein remodelling and activation of
inflammatory pathways. In acute coronary syndrome, high sPLA2-IIA
levels predict major cardiovascular events. In this trial on 625 subjects, it
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has been shown that Varespladib reduced the levels of LDL-C, hs-CRP,
sPLA2-IIA and positive trends were noted for unstable angina/myocardial
infarction. Based on these data, a 6,500 subject Phase III trial is planned
(Rosenson et al., 2011).
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX1) is a potent
regulator of systemic atherosclerosis. In this study the authors developed a
LOX1-targeted liposomal rho-kinase inhibitor and examined the therapeutic
effect on carotid intimal hypertrophy in rats. Liposomes conjugated with
anti-LOX1 antibody inhibited carotid intimal hypertrophy. The new
liposomal drug delivery system targeting LOX1 could become a therapeutic
strategy for atherosclerotic diseases (Saito et al., 2011). Many targeted
therapies have been developed following the discovery of specific markers;
i. e. bevacizumab for VEGF, statin for lipid/cholesterol
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Biological pathway Example of marker involved Atherosclerotic plaque development
processes 
Lipid metabolism LDL, HDL, TG LDL lipid accumulation in the core
Inflammation IL6, hsCRP, SAA, PAPP-A, TNF-
alfa
SMC and macrophages accumulation in
in the lipid core.
  
Angiogenesis VEGF Formation of new vessels
Proteolysis M M P - 9 , M M P - 1 2 , C C P ’s ,
TIMP’s
Release of proteolytic enzymes 
t h a t d e g r a d e the ex t r ace l lu l a r
matrix (cap erosion, rupture, acute
neurological events)
 
Hypoxia Indirect markers: Cytokines,
MMP’s
Direct marker unknow
promotes angiogenesis, increases
production of cytokines and MMPs
(causing plaque destabilization)
Apoptosis Annexin 5, 
Others unknow
SMC and Macrophages accumulation
in the lipid core causing rupture ?
Thrombosis  Instability 
Calcification BMP-2, Osteopontin increase the plaque fragility
Table 4: Emerging biomarkers
Markers of our study: inflammation biomarker
C-reactive protein
The central role of the inflammation during the various stages of the
atherogenesis is now clear. The activity of the macrophages determines the
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instability of the plaque owing to the erosion of the fibrous cap and the
alterations in the internal microvessels. The phlogistic activity manifests
itself also with the presence of various molecules – cytokines, chemokines
and interleukins – that act as a stimulus for the leucocytes at the level of the
plaque (Ross et al., 1993).
Many studies consider these molecular markers as predictive factors of
cardiovascular events. In particular, research focuses on cellular adhesion
molecules, cytokines, chemokines, acute-phase molecules such as
fibrinogen and C-reactive Protein (CRP) (Libby et al., 2002)..
CRP has been widely studied; indeed, the literature includes many
publications describing its role as a marker of cardiovascular risk.
CRP is a member of the pentraxin family of proteins; its production in the
liver is regulated by serum levels of IL-6, although IL-1 and TNF can also
contribute to its release. The half-life of CRP is about 19 hours and it is
produced at normal levels in conditions of good health and at higher levels
in conditions of disease. The main activity of CRP consists in binding to the
macrophage Fc receptors and stimulate the phagocytosis of cells that have
died through apoptosis or necrosis. Recent studies have identified areas
outside the liver where this protein is produced such as the atherosclerotic
lesions (by macrophages and smooth-muscle cells), the kidneys, the
neurons and the alveolar macrophages. The lipid peroxidation and the
infectious state activate the release of CRP with the release of inflammatory
cytokines (Thompson et al., 1999; Yasojima et al., 2001)..
CRP as a marker of risk. Many studies have demonstrated the predictive
role of CRP for cardiovascular events such as myocardial infarction,
coronary heart diseases, sudden death, peripheral artery disease and stroke
in apparently healthy subjects (Ridker et al., 2003; Ridker et al., 2000;
Pearson et al., 2003; Jialal et al., 2003).
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As regards these data, the American Heart Association and Centers for
Disease Control and Prevention have indicated that CRP can be used as a
marker of risk for cardiovascular pathologies. 
The recommendations indicate that: 
·      CRP< 1mg/l: low risk
·      CRP between 1 and 3 mg/l: intermediate risk
·      CRP> 3 mg/l: high risk.
However, if the levels are higher than 10 mg/l, CRP cannot be used as a
marker of cardiovascular risk, because other inflammatory (infectious or
traumatic) processes need to be excluded. In the primary prevention of
cardiovascular events, it is necessary to use the “high sensitivity” CRP test
(hs-CRP) and the patient must not present any acute inflammatory
conditions for at least two weeks. 
Some of the conditions associated with higher levels of CRP are: obesity,
chronic inflammatory diseases, metabolic syndrome and diabetes mellitus
type 2. 
CRP as an agent of inflammation. The role of CRP as a risk factor has been
established; however, its presence at the level of the atherosclerotic lesions
has led to look for any possible activity in the development of the plaque.
The limitation of these studies lies in the fact that the evaluation of the
activity of this protein is carried out in vitro or on animal models but not yet
in vivo on human subjects. A list of the cellular activities related to CRP is
presented below.
CRP and macrophages: - CRP stimulates the release of reactive oxygen
species,a
- it stimulates the release of IL-6 and TNF,b
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- it increases the release of MMP-1,c
- it enhances the phagocytosis of cholesterol.d
 
CRP and endothelial cells: - CRP stimulates the expression of adhesion
molecules on monocytes (ICAM-1 and VCAM-
1),e
 - it correlates with vasoreactivity and
endothelial dysfunction by inhibiting the
production of nitric oxide (NO),, f,g 
- it inhibits the production of prostacyclins,
which inhibit the platelet aggregation and the
proliferation of smooth-muscle cells,h
-it stimulates the expression of PAI-1
(plasminogen activator inhibitor-1), which
presents an atherogenic and procoagulant
activity.i
 
CRP and sm.-musc. Cells: - CRP stimulates the expression of AT1R (angiotensin
type1 receptor), which presents an atherogenic
activity,j
– it stimulates the cellular proliferation.k
CRP role is well-characterized in the coronary district but its predictive role
in vulnerable plaque is still unknown.
*references: a; Tebo et al.,1991; b: Ballouet al., 1992; c: Williams et al.,
2004; d:Chang et al., 2002); e: Pasceri et al., 2000; f: Fichtlscherer et al.,
2000; g: Venugopal et al., 2002; h: Venugopal et al., 2003; i:. Devaraj et al.,
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2003; j: Nickenig et al., 2002;.k: Hattori et al,. 2003
Serum amyloid A-protein
SAA is the most impressive of the acute-phase proteins, increasing within
24 h by up to 1000-fold in response to various injuries including trauma,
infection, inflammation, and neoplasia (Urieli-Shoval et al., 1998). SAAs
can be divided into two groups; the first group comprises the well-
characterized acute phase SAAs that associate with HDL during
inflammation, thereby remodelling the HDL particle by displacing
apolipoprotein (apo)A-I. The second group consists of the recently
discovered constitutive SAAs, mouse SAA5 and human SAA4. SAA4 is
found to be associated with a distinct subclass of HDL particles unrelated to
those involved in the initial cholesterol transfer from cells (de Beer et al.,
1995). 
The human SAA gene family is composed of four discrete loci containing
two highly homologous genes, SAA1 and SAA2, and two less related
genes, SAA3 and SAA4. The gene for SAA4 is constitutively expressed and
its protein product is a constituent of normal, non-acute-phase high-density
lipoprotein. The liver has been considered the primary site of expression.  It
was demonstrated that the SAA mRNA and protein are widely expressed in
many histologically normal human tissues, including stomach, small and
large intestine, tonsil, breast, prostate, thyroid, lung, pancreas, kidney, skin
epidermis, and brain neurons. (Urieli–Shoval, 1998).
SAA production is up-regulated by proinflammatory mediators, notably the
interleukins IL-1 and IL-6 and the tumour necrosis factor TNF-α [7], and
conversely, SAA has been shown to induce the production of cytokines in
THP-1 monocytes and in neutrophils.(Niemi et al. 2006) This clustering
may be due to the fact that SAA can act as a mast cell chemoattractant
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(Niemi et al. 2006). Katri Niemi et al. (2006) showed that SAA can activate
human mast cells as indicated by the significant induction of TNF-α and IL-
1β production. High levels of SAA activate mast cells to degranulate and to
release their stores of cytoplasmic neutral proteases, notably tryptase. SAA4
mRNA (express costituvely) and protein expression in macrophage-derived
foam cells of coronary and carotid arteries suggested a specific role of
SAA4 during inflammation including atherosclerosis (A Hrzenjak et al.,
Protein Engineering 14(12):949-952, 2001). Further credence for
extrahepatic expression of SAA4 mRNA is derived from studies in human
lesion material. This raises the possibility of similar proatherogenic
properties of human SAA4 as reported for A-SAA (Andelko Hrzenjak et al
2001). 
Ridker et al have shown that serum SAA concentration is a significant
predictor of the risk of cardiovascular events more effective than the levels
of LDL-cholesterol or total cholesterol, indicating a cardiovascular relative
risk factor of 3.
SAA is also expressed in normal cerebral tissue; the pyramidal neurons of
the cerebral cortex and Purkinje cells of the cerebellum. (Urieli–Shoval,
1998). A-apoSAA mRNA was detected in Alzheimer's disease and in
rheumatoid arthritis synovial tissue and cells (Liang et al., 1997; Kumon et
al., 1999). SAA plasma concentration increased after cerebral infarction; the
concentration of SAA depending on the clinical severity of the ischemic
stroke. SAA was found also to be a sensitive early indicator of possible
infectious complications after the cerebral infarction (Hzecka et al., 2000).
SAA is expressed in a variety of tissue but at the moment only few studies
have analysed its involvement in carotid plaque district in correlation to
cerebral injuries.
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Pregnancy-Associated Plasma Protein-A 
Pregnancy-Associated Plasma Protein-A , a high molecular weight zinc
binding metalloproteinase, was first found in 1974 in the third-trimester
plasma of pregnant women (Lin et al., 1974). PAPP-A has proteolytic
activity when it is not bind to proMBP sub-Unit. The main activity of
freePAPP-A is to cleave insulin-like growth factor-1 (IGF-1) from its
binding protein-4, thereby increasing the accessibility of free IGF-1 to
tissues. 
In vitro studies showed that IGF activate macrophages, chemotaxis, LDL
cholesterol uptake by macrophages and release of pro-inflammatory
cytokines, thus suggesting a pro-atherogenic activity. (Renier et al., 1996;
Bayes-Genis et al., 2000).
The study of Sangiorgi et al. suggests that PAPP-A is a specific marker of
carotid plaque vulnerability and that an increase of PAPP-A serum level is
related to the progress of unstable plaque (Sangiorgi et al., 2006).
However there is contradiction through literature towards the role of PAPP-
A; pro-atherogenic or repairing factor? Several lines of evidence indicate
that PAPP-A is induced in response to, and within, damaged tissues, as a
promoter of repair, in virtue of its IGF-1-dependent actions on
vasculogenesis, vasodilation, cell preconditioning, cell survival, and
insulin-sensitivity. (Chen et al., 2003). PAPP-A may have important and
pivotal roles in local cellular function related to wound healing, bone
remodeling, atherosclerotic plaque development, angiogenesis and several
aspects of human reproduction (Qin et al., 2002). A study showed that
PAPP-A is able to stimulate matrix mineralization; BMP-2 is an inducer of
the osteoblast transcription factors RUNX2 and OSX which are crucial for
bone formation. OSX sees to operate downstream of RUNX2. The
cooperation between PAPP-A and BMP-2 in matrix mineralization could
involve Osx, but remains unclear. The data of the study suggests that PAPP-
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A, demonstrated to be regulated by BMP-2, is also involved in angiogenesis
as new blood vessel formation. (PAPP-A is involved in matrix
mineralization of human adult mesenchymal stem cells and angiogenesis in
the chick CAM Julie Jadlowiec1, 2, 3, Diana Dongell2, Jason Smith3,
Cheryl Conover4 and Phil Campbell)
Some studies reported that circulating PAPP-A is not an early marker of
acute myocardial infarction. (Jadlowiec et al., 2005). It is important to
underline that the PAPP-A form that becomes elevated in ACS is not
complexed with proMBP which is hereby defined as free PAPP-A. In 2010,
a study including 267 patients free PAPP-A seems to be superior as a
prognostic marker compared to total PAPP-A (Lund et al., 2010). Thus, the
concentrations obtained with the assays do not accurately reflect the amount
of PAPP-A in  acute coronary syndromes. The clinical value is most
possibly underestimated when total PAPP-A is measured in ACS patients
due to the presence of partial overlap between the distribution of PAPP-A in
normal population (complexed form only) and distribution of PAPP-A in
ACS patients (complexed and free forms).
The validation results from clinical studies evaluating free PAPP-A serum
and tissue level remain to be seen and correlated with angiogenesis and
calcification in atheromasic plaque.
Neuron-specific enolase
Several previous studies have indicated that monitoring the levels of
neuron- or astroglia-specific proteins in the serum and cerebrospinal fluid
could be a useful approach for evaluating the severity of central nervous
system injury (e.g. traumatic brain injury, cerebral infraction, intracranial
hemorrhage). 
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The marker proposed is the neuron-specific enolase (NSE), which is a
highly soluble intracellular protein principally located in neuronal
cytoplasm and in neuroendocrine cells.  NSE is readily secreted into the
cerebrospinal fluid and blood after tissue injury, and has been shown to
have a biological half-life of 48 hours. Kaiser et al. 1989. Marangos et al.,
1987).
Leukocytes have been proposed as a useful peripheral model to study
mental pathologies (Gladkevich et al. 2004; Iga et al. 2008; Rokutan et al.
2005), since their expression profiles have shown similarities to those
observed for brain cells, especially for genes encoding neurotransmitter
receptors and transporters, stress mediators, cytokines, hormones, and
growth factors (Glatt et al. 2005 ; Sullivan et al. 2006).
Thus our interest to determine if the circulatory levels of PAPP-A and NSE
mRNA reflects cerebral injuries occurring during CAS or CEA procedure. 
Markers of our study: neoangiogenesis biomarkers
Neoangiogenesis
Neoangiogenesis is the growth of new blood vessels from pre-existing
vessels. Growth within the atherosclerotic plaque may destabilize the
structure leading to rupture. The vascularization of atherosclerotic plaque is
a key element in the development and progression of the lesion. Neovessels
may destabilize the plaque structure leading to rupture with clinical
consequences; some of the clinical features correlated to plaque
neoangiogenesis are represented in sketch X (Virmani R. et al., 2005;
Kolodgie et al., 2003). The presence of neovascularization in carotid plaque
increases plaque instability and therefore results in an increased risk of
developing neurological events (Dunmore et al., 2007; Mofidi et al, 2008),
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(table 5) 
Table 5: Clinical features correlated to plaque neoangiogenesis
Boerhaave (approximately in 1750) suggested that hardening of the arterial
wall occurred when the small arteries feeding the muscular layer constricted
and hardened (ossified), which is the first description of the vasa vasorum
(the vessel within the vessel) directly involved in the angiogenic process
(Acierno LJ, 1994). In 1995, Kumamoto et al. was able to show in diseased
atherosclerotic epicardial arteries that intimal vessels originated 28 times
more frequently from the adventitial vasa vasorum than those originating
from the lumen. He was also able to reveal that intimal-medial
neovascularization was closely associated with the inflammatory reaction
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within the plaque, established early in the atherosclerotic process, and
capable of regression. Most authors feel that the intimal-medial
neovascularization arises more frequently from the adventitial vasa
vasorum. Both adventitial and luminal microvessels are very fragile and
prone to leak and rupture creating intraplaque hemorrhages. Kwon reported
rapid, extensive development of vasa vasorum angiogenesis in coronary
vessels. These were induced by a high fat diet in three months (Kwon et al.,
1998; Kantor 1999). Burke and Virmani revealed that plaque rupture in
sudden death is related to vasa vasorum angiogenesis in addition to the
chronic macrophage inflammatory response (Burke et al., 1999). Thus, later
in the atherosclerotic process the angiogenic vasa vasorum may be more
responsible for the delivery of the previously discussed harmful molecules
and substrates than diffusion through the traditional endothelial lumen
surface early in the atherosclerotic process.
Bargers in 1984, was able to show a "malignant like" infiltration of
microvessels into the media and intima of the atherosclerotic diseased
segments; neovascularization of the vessel wall originate from the
adventitial vasa vasorum. In the healthy segments of the same coronary
artery there is no involvement of angiogenesis. 
The identification of lesions, that are rich of vascular components,
represents an additional risk assessment of the vulnerable patient. VEGF is
the growth factor mainly involved in the angiogenic stimulus within the
plaque but can also be identified in the blood level, representing a possible
risk marker. Also instrumental methods, such as CEUS, may allow the
identification of atherosclerotic lesions with increased neovascularization,
thus quickly identifying lesions at higher risk or rupture.
Vascular Endothelial Growth Factor 
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The Vascular Endothelial Growth Factor (VEGF) is a molecule that is
fundamental for the development of the blood vessels. VEGF is expressed
in the embryonic period, during the development of the vascular tree,
during the growth stages and in the processes of tissue repair. Angiogenesis
is physiologically regulated by VEGF and its inhibitors. When the
regulation goes awry, the formation of blood vessels becomes either
excessive or insufficient.
The most significant stimulus for the cellular production and release of
VEGF, in the adult, is represented by hypoxia; the cells that are responsible
for this production can be both normal and tumorous. Many studies have
focused their attention on the role of VEGF in the development of solid
neoplasms, which need new vascular structures for their growth and, thus,
release VEGF to form them.94
Only in the past few years, the role of this molecule has been taken into
account also with respect to atherogenesis. In the atherosclerotic lesions, the
hypoxia and the release of molecules by the macrophages result in the
expression of VEGF. Inside the plaque, some small vessels appear and
determine the instability of the plaque, as they enhance the recruitment of
macrophages and can cause internal haemorrhages. VEGF is expressed by
endothelial cells, macrophages and smooth-muscle cells.
Its activity in the plaque is determined by the receptors involved:
VEGFR1: (fms-related tyrosine kinase 1, FLT-1) it determines the pro-
inflammatory activity,
VEGFR2: (kinase insert domain-containing receptor, KDR) it regulates
angiogenesis.
Its activity is highlighted by experimental studies on animals, during which
the administration of recombinant human VEGF increases the size of the
atherosclerotic lesions, their vascularization and the number of
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macrophages – compared with controls treated with placebo. In other
studies on animals, angiostatin, which is an inhibitor of VEGF, reduces the
accumulation of macrophages and the size of atherosclerotic lesions. Over
the past few years, many studies have demonstrated that the presence of
VEGF in atherosclerotic plaque is associated with instability due to both
angiogenesis and the degree of the internal inflammation.95-98
VEGF targeted therapy. There are medications that are currently used in the
treatment of neoplasms and are able to inhibit neoangiogenesis. Their
possible role in reducing the progression of the atherosclerotic lesions is
demonstrated in animal models, but their application in the clinical practice
is still debated. This is due to the fact that, beside the possible benefit of
reducing the intraplaque vascularization, there may be adverse ischemic
effects in other areas.99 
A prototypic VEGF inhibitor used in many cancer clinical trials is the
monoclonal anti-VEGF antibody, bevacizumab (Murukesh et al., 2010). 
The role of VEGF in the atherosclerotic plaque, including the carotid ones,
is clear. Studies are trying to confirm the hypothesis that this molecule can
be considered as a marker of atherosclerotic risk, in order to identify carotid
lesions of high cerebrovascular risk.
Nestin
Nestin is an intermediate filament protein expressed in neural and
mesenchymal stem cells, as well as in a variety of progenitors cells (Wagner
et al., 2006). It was also seen that Nestin is an angiogenic marker for newly
formed microvessels, and numerous Nestin-positive microvessels were
described in tumours of control mice (Ramasamy et al. 2011). Moreover, a
recent study showed that Nestin is expressed in newly forming blood
vessels and also in a high number of endothelial cells after myocardial
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infarction (Wagner et al., 2006). A previous study showed that medial
vascular smooth muscle cells in the developing arteries potently express
Nestin, but its expression is abolished in adult arteries (Oikawa et al., 2010).
In adult tissue, Nestin expression may be restricted to newly formed
endothelial cells generated during angiogenesis (Teranishi et al., 2007). It is
therefore believed that Nestin expression, representing an early endothelial
differentiation or an endothelial progenitor phenotype, could be a reliable
marker of “progenitor-committed” endothelial cells and/or of a “young”
endothelium. 
Variants in the Nestin gene are associated with coronary heart disease. The
Nestin gene may play a role in the development of both primary and
restenotic coronary artery plaque (Meng et al., 2008). Nestin expression in
carotid plaque lesions has not yet been studied. Nowadays the known
transcription factors regulating Nestin are: Pou, Sox, TTF-1 and WT1
(Wagner et al., 2006; Pelizzoli et al., 2008). 
Wilms tumour suppressor 
The Wilms tumour suppressor (WT1) encodes a protein with four C-
terminal Zn-fingers characteristically found in the transcription factor
(figure 8). 
Figure 8: WT1 protein structure. 
WT was originally described in the paediatric Wilms’ tumour of the kidney,
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but its involvement has been demonstrated in a variety of other tumours and
tumour cell lines (Hohenstein et al., 2006; Wagner et al., 2008). Some
recent studies showed the involvement of WT1 as an activator of the Nestin
gene (Hohenstein et al., 2006), and the co-localization of WT1 and Nestin
during the different development steps in embryogenesis (Wagner et al.,
2006). The functions of WT1 are not only limited to the kidney and
promoter of tumour angiogenesis but involve the heart and vascular system
as well. Recent findings show the importance of WT1 in heart and coronary
vessel development and the identified molecular mechanisms (Sholz et al.,
2009). 
Therefore the new interest towards WT1 function in neoangiogenesis during
plaque formation.
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AIM 
 
In this research our target was to identify local or circulating proteins 
associated to plaque vulnerability and to the risk of cerebral 
embolization in order to recognize vulnerable patients for systemic 
cardiovascular adverse events.  
 
Microembolization during the stenting procedure can cause cerebral lesions. 
During the CAS procedure stent are mostly associated to distal filters that 
avoid the diffusion of fragments of emboli detached during the procedure.  
The first part of the study wants to establish the correlation between cerebral 
lesions occurring during CAS and hsCRP, SAA, VEGF, PAPP-A and mRNA 
NSE. 
Indication to CEA is commonly determined by percent of stenosis as well as 
neurological symptoms and clinical conditions. High plaque embolic 
potential is defined as ‘vulnerability’; however, its characterisation is not 
universally used for carotid revascularisation. In the second part of the study, 
we investigated different methods to identify carotid vulnerable plaque, 
imaging technique and histological parameters as thin fibrous cap thickness, 
phlogosis and microvessel density, serological markers and molecular 
markers.  
Lastly, since neovessels’ density correlates with plaque destabilization, 
neoangiogenesis represents a crucial step in atherosclerosis. Vasa Vasorum 
(VV) neovasculogenic potential and involvement in atherosclerosis are now 
widely accepted, and related to the presence of endothelial progenitor cells. 
In order to clarify the trigger mechanism of neoangiogenesis in plaques, we 
studied the morphology of VV in healthy and diseased arteries and their 
immunohistochemical (IHC) expression of markers of disease and 
endothelial progenitor cells. 
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Materials and methods 
 
 
Carotid artery stenting study 
 
Patients 
In the period between June 2009 and December 2009 a series of 
consecutive patients with ≥70% carotid artery stenosis (North American 
Symptomatic Carotid Endarterectomy Trial Collaborators, 1991) were 
submitted to CAS, according to Society for Vascular Surgery 
recommendations (Hobson et al., 2008). Demographic data, symptoms 
(amaurosis fugax, transient ischemic attack, minor and major stroke), 
vascular risk factors (hypertension, coronary artery disease, chronic 
obstructive pulmonary disease, dyslipidemia, diabetes mellitus, current 
smoking, chronic renal failure based on a glomerular filtration rate < 60 
ml/min) and current therapy (acetylsalicylic acid, anticoagulant, 
hydroxymethyl glutaryl coenzyme A reductase inhibitor) were all recorded 
in a database software. All patients gave the appropriate informed consent 
for the study before the CAS procedure. 
 
Carotid plaque structure analysis. 
Carotid plaques were evaluated by duplex scan ultrasound (Philips, IU 22 ) 
to determine the role of plaque structure in CAS embolization; the images 
were digitally stored for later evaluation by an expert operator blinded to 
the study. The plaques were divided into homogeneous and 
dishomogeneous, according to gray scale measurement (GSM). GSM was 
analysed for each plaque with the ImageJ software 
(http://rsbweb.nih.gov/ij/) using the histogram function that gives a mean 
gray of pixels of the region of interest. Dishomogeneous plaques were 
identified with GSM<50 (Biasi et al., 1999), or in the presence of an 
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ulceration (defined as a surface recess greater than 2 mm deep and 2 mm 
long).  
 
CAS procedure. 
CAS was performed as previously described (Faggioli et al., 2007). Briefly, 
patients were taken to the angiographic suite after cardiological evaluation 
and medicated with aspirin 100 mg and clopidogrel 75 mg for 3 days before 
the procedure. All procedures were performed under local anaesthesia, 
systemic heparinisation and an 8F groin introducer. Common carotid 
cannulation was achieved with 40° Boston Scientific® or Medtronic® HS I 
and II catheters over a Terumo® stiff guide wire. When cannulation was 
not achievable by these means, several different alternative techniques were 
used (i.e., buddy wire, coaxial). Brachial or carotid access was not 
attempted in any case. Routine cerebral protection was performed using 
Filterwire EZ with 100 µm diameter pores (Boston Scientific®) and 
stenting by closed-cell (Wallstent, Boston Scientific®). ‘Technical success’ 
was defined as the ability to treat the stenosis with less than 30% residual 
stenosis. Neurological outcome was evaluated both at the end of the 
procedure and in the following 24 h by a neurologist according to the NIH 
stroke scale and the modified Rankin scale. 
 
Filter analysis by light microscopy. 
At the end of the CAS procedure filters were recovered, gently washed in 
physiological solution and immediately fixed in 10% neutral, buffered pH 
6.9 formalin. Macro photographs of the device in its integrity were taken 
under a stereomicroscope. After removal of the metallic wire, the filter was 
cut into two equal portions and flattened; the first sample was mounted onto 
glass slides using Canada Balsam (Sigma-Aldrich C1795) whereas the 
second one was stored in formalin for SEM examination. Morphometric 
analysis was performed under a light microscope (Leitz Wetzlak, Germany) 
connected with a CCD camera Olympus CX42. Images were acquired using 
Materials and methods 
 
 49 
Image-Pro Plus software (Media Cybernetics) and processed with ImageJ 
software (http://rsbweb.nih.gov/ij/). An average of 30 fields per filter was 
acquired and the total area evaluated for each filter was 0,12 mm2 at a 
magnification of 10X.  
The percentage of membrane surface occupied by debris was expressed as 
percentage of surface involvement (SI). Images were converted to stacks 
composed by 6 fields each, transformed in montage, converted from colour 
images to 8-bit greyscale with the scale set at 0.41 pixel/µm. The boundary 
of the filters was delineated to calculate the total area for each stack 
(13.2mm2), and then the lower and upper threshold values were set to 
measure the percentage of the covered area of interest (Fig. 1B). 
 
Figure 1: Image stacks to evaluate area covered by debris in filters’ 
membrane. 
 
The number of pores occluded (PO) by thrombo-embolic material, with a 
minimum mean size of 40 µm, and the total number of non-occluded pores 
was quantified and expressed as a percentage. For histology and debris 
characterisation, the apex of some filters with visible adherent material was 
recovered, dehydrated as before and embedded in paraffin for 1h; 3 µm 
thick sections were stained with hematoxylin-eosin (HE). 
 
Filter analysis by scanning electron microscopy. 
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Scanning electron microscopy (SEM) was performed to characterize the 
dimension and the type of embolic debris adherent to the filter device inner 
surface. 
Filters were embedded in ashless paper filters, washed with phosphate 
buffer 0.15 M and post-fixed in 1% osmium tetroxide for 15 min at RT. 
Then the filters were washed for 15 min in distilled water, dehydrated with 
graded steps of ethanol (70%, 95% and 100% ethanol; 15 min each step) 
and dried with hexamethyldisilazene (HMDS, Fluka, Steinheim, Germany) 
for 30 min at RT. The dried filters were accurately flattened and mounted 
on aluminium stubs (Multilab Type stub pin 1/2’’, Surrey, UK), and sputter 
coated with a 10 nm thick layer of gold in a Balzers MED 010 sputtering 
device (Balzer Union FL 9496 Fürstentum Liechtenstein). Then samples 
were observed using a Philips 505 Scanning Electron Microscope at 15 kV. 
Images were processed with ImageJ. The size of the particles was evaluated 
by measuring the length of major and minor axis using ImageJ. 
 
Cerebral lesions assessment: DW-MRI. 
Diffusion weighted imaging scans were obtained both one to three days 
before CAS and during the first 24 hours after the procedure. A 1.5T 
General Electrics Medical Systems (Milwaukee, Wisc) Signa Horizon LX 
whole-body scanner with a quadrature birdcage headcoil was used. 
Hyperintense lesions were visually identified on the post-CAS DW-MRI 
images. Identification was confirmed by the absence of hyperintensity on 
the corresponding pre-CAS DW-MRI images. The volume and the number 
of lesions were assessed semi-automatically, with final revision by one of 
the specialized physicians involved in the study (R.L., C.T.). The volume of 
the lesions was quantified by defining a threshold for the difference 
between pre-CAS and post-CAS image intensities, and counting the number 
of pixels where the difference was greater than this threshold. Classification 
of new brain lesions was based on the vascular territory in which they 
occurred. New lesions were defined “ipsilateral (IL)” if located in the 
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hemisphere ipsilateral to the side of the treated carotid bifurcation; or “non-
ipsilateral (CL)” if located in the hemisphere contralateral to it, in the 
posterior territory, or in both the ipsilateral and contralateral hemisphere.  
(For a detailed description of the technical aspects of the DW-MRI please 
refers to Faggioli et al., 2009) 
 
Carotid endarterectomy specimens 
 
Patients 
A series of consecutive patients with either symptomatic or asymptomatic 
carotid artery stenosis >=70% were submitted to carotid endarterectomy 
(CEA), according to ESVS and Society of Vascular Surgeons (SVS) 
recommendations. Symptomatic carotid stenosis, defined as ipsilateral 
cerebral ischaemic events (major or minor stroke or transient ischaemic 
attack (TIA) or amaurosis fugax) that occurred in the last 6 months, were 
evaluated by independent in-hospital neurologists. Epidemiological data, 
neurological symptoms, vascular risk factors (hypertension, coronary-artery 
disease, chronic-obstructive pulmonary disease, dyslipidaemia, diabetes 
mellitus, current smoking and chronic-renal failure) and current therapy 
(acetylsalicylic acid (ASA), anticoagulant and hydroxymethyl glutaryl 
coenzyme A reductase inhibitor) were recorded in a database software. 
Emergency procedures for acute ischaemic symptoms were not included in 
the study. Preoperative cerebral computed tomography (CT) scan was 
performed in all cases to identify possible ischaemic lesions. CEUS plaque 
evaluation was performed in the days immediately before surgery. All 
patients gave their informed consent for the study before CEA, which was 
performed in a standard fashion through a laterocervical approach. 
 
CT scan 
Cerebral CT was performed in all patients using a multi-slice (16-slice) GE 
Light Speed scanner (General Electric, Milwaukee, WI, USA). According 
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to Mofidi et al. the presence of cerebral ischaemic lesions ipsilateral to the 
side of the carotid plaque was considered a positive CT evaluation. Cerebral 
ischaemic lesions were defined as areas of low attenuation, involving both 
grey and white matter or focal areas of encephalomalacia. Cerebral CT 
evaluation was performed blindly by two different operators within 2 weeks 
before surgery. 
 
CEUS 
Carotid ultrasonography was performed with an ultrasound machine 
(Philips IU22, Amsterdam, the Netherlands) by a blinded expert operator 
(with more than 100 carotid ultrasound examinations performed per year), 
within 2 weeks before surgery. A contrast-specific software operating at 
low mechanical index was used. The power modulation mode (IU22) was 
used. The second-generation echo-contrast agent, SonoVue® (Bracco, 
Milan, Italy), was employed. SonoVue® is based on microbubbles 
stabilized by phospholipids and filled with sulphur hexafluoride with a 
median diameter of 2.5 mm. The low solubility and the high resistance of 
the shell to the mechanical effect of the ultrasound (US) beam allow this 
contrast agent to act for a long period of time (10 min). The contrast 
solution is prepared immediately before administration by adding 5 ml of 
sterile saline solution (0.9% NaCl) to the vial and by vigorously shaking it 
for at least 20 s. SonoVue® was administered as a bolus at a dose of 5ml 
and was injected intravenously through a 20-gauge intravenous catheter, 
followed by a 10-ml-flush of saline water (0.9% NaCl). A linear probe with 
a transmission frequency of 10-12 MHz was used by a blinded expert 
operator. Common, internal and external carotid arteries were visualized in 
the longitudinal and the transverse planes. Images of plaques in B, Colour 
and Power modes were digitally stored. CEUS evaluation was performed as 
follows. After presetting real-time, contrast-enhanced imaging modality 
with coded pulse-inversion technique, image settings were adjusted for 
maximising the contrast signal. The mechanical index was preset to 0.13 
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and the frame rate to 12 per s, to reduce microbubble destruction, with 
image depth at 3-5 cm, according to the patients’ anatomical necks 
characteristics. The longitudinal carotid plaques images in real-time 
visualisation with the presence of microbubbles in carotid lumen and in the 
plaques’ microvessels were digitally stored for later outline-blinded 
software analysis. Image storing was performed for at least 10 min, from 
the moment of injection to the time of decreasing microbubbles 
concentration in carotid lumen. QLab® (Philips Healthcare, India) software 
was used for the outline plaques vascularisation analysis, obtaining the 
maximum level of dB-Enhanced (dB-E) at the peak of microbubble's 
concentration for each plaque analysed. The stored images sequences were 
evaluated identifying the carotid plaque, delineating the region of interest 
and eventually performing the software analysis of microbubbles 
concentration within the plaques and recording dB-E values (Fig. 2). 
 
 
Figure 2: Image sequences of carotid plaque before (A) and after (B) 
CEUS microvessel detection. Panel B shows the area within the plaque 
filled with neovessels (red arrows). In panel A, only the border of the 
plaque is visible (black arrows) showing two ulcers.  
 
 
 
Histological analysis of carotid plaque 
Carotid plaques were removed in full during surgery to preserve the plaque 
structure. After 24 h of decalcification, samples were cut in serial sections 
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and the area with the highest percentage of stenosis was identified and 
defined as the area of interest for further analysis. Plaque tissue samples 
were fixed in formalin buffered 10% and embedded in paraffin; 5-mm-thick 
haematoxylin and eosin-stained sections were observed under a light 
microscope (LM,Olympus CX42). Carotid atherosclerotic lesions were 
defined according to the American Heart Association (AHA) classification 
and grouped as type I to VI ranging from the initial lesion to the 
complicated lesion. An experienced pathologist performed all 
histopathological analysis.  
 
Immunohistochemical assay on carotid plaque 
Formalin-fixed paraffin embedded 5-mm-thick tissue carotid sections were 
rehydrated through graded steps of ethanol absolute (Xilol 30min, 100% 10 
min, 95% 5 min, 70% 5 min). Antigen retrieval was performed with a heat-
mediated method at 1 atm, 120 °C for 20 min in a citrate buffer solution 
(pH 6) and cooling for 20 min. Endogenous peroxidase activity was 
blocked with 3% H2O2 in absolute methanol for 10min at room 
temperature (rt), in the dark. Antigene-antibody reaction was developed 
with the NovoLink Polymer Detection Kit (Novocastra, Newcastle, UK). 
Sections were incubated overnight in a wet chamber at 4 °C with the tested 
antibody (represented in table 1). Then, sections were incubated with 
NovoLink® Polymer for 30 min at rt, and subsequently with 
diaminobenzidine NovoLink® DAB Substrate Buffer) for 30s to 2 min. 
Cell nuclei were stained with Mayer’s haematoxylin (Sigma Chemicals). 
Negative controls were done without the primary antibody. After 
dehydratation samples were mounted onto glass slides using Canada 
Balsam (Sigma- Aldrich C1795). The sections were observed under a light  
microscope (Leitz Wetzlak, Germany 12 V max, 100W) connected with a 
charge-coupled device (CCD) camera Olympus CX42. Images were 
acquired using Image-Pro Plus software (Media Cybernetics 
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http://www.mediacy.com) and processed with ImageJ free software 
(http://rsbweb.nih.gov/ij/). 
 
Antibodies Clone Dilution Evaluates Manufacturer 
CD3 SP7 
(Rabbit) 
1:100 Inflammation 
T lymphocytes 
Neomarker 
USA 
CD68 PG-M1 
(Mouse) 
1:200 Inflammation 
Monocytes 
Dako A/S, 
Denmark 
dPAPP-A (PD4 
(Mouse) 
1:1200 Macrophages-
EC 
HyTest 
Finland 
Mast  cell 
tryptase 
AA1 
(Mouse) 
1:50 Inflammation 
Mast cells 
Dako A/S 
Denmark 
CD31 JC70 
(Mouse) 
1:50 Vessels density Dako A/S 
Denmark 
CD34 Q-BEnd-
10 
(Mouse) 
1:100 Vessel density Dako A/S, C, 
Denmark 
Nestin 10C2 1:400 Immature 
vessels, ECPs 
Millipore 
USA 
WT1 6F-H2 
(Mouse) 
Pre-
diluted 
Immature 
vessels, ECPs 
Ventana, Roche 
SAA4 EPR2926 
(Rabbit) 
1:100 Macrophages-
foam cells in 
Atheroma 
Epitomics 
USA 
a-SMA 1A4 
(Mouse) 
1:9000 Cellularity 
(Vascular wall 
smooth muscle 
cells) 
Sigma, Saint 
Louis, Missouri, 
USA 
All were monoclonal, **EPC: endothelial progenitors cells  
 
Table 1: Antibodies used during immunohistochemical analysis 
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Histological evaluation of vulnerability  
Vulnerable plaques generally have five histologic hallmarks compared with 
stable plaques: a larger lipid core (>40% of total lesion area), a thinner 
fibrous cap, inflammatory cells (NASC 1991; ECST 1991; Bluth et al., 
1988; Kern et al., 2004), calcified lesions (Grant et al., 2003) and 
neoangiogenesis (EI-Barghouty N., 1995). We define vulnerability of the 
plaque following these last assumptions. Extension of calcification and the 
lipid core was evaluated on entire circumferential arterial sections dividing 
the quadrant into four equal fields. The extension was scored in numerical 
values ranging from 0 to 4 (0=>no calcification or core, 1=>1/ 4 of the field 
occupied by calcification or core, 2=> 2/4, 3=> 3/4 and 4=> 4/4 all fields 
occupied). Fibrous cap thickness was measured with a score of 0 (>200 
mm) or 1 (<200 mm), and by evaluating intraplaque haemorrhage with a 
value of 0 if absent or 1 if present. Cellular inflammation infiltrate was 
characterised with the following immunohistochemical markers: CD68 as a 
macrophage marker, Tryptase (serine proteinase stored in the mast cell 
secretory granules) as a mast cell marker and CD3 as a lymphocyte marker. 
Microvessel density count was obtained with CD34 as a marker of 
immature and mature endothelial cells (Ecs). Table 2 summarises these 
histological features in score. 
 
 
Histological features Parameters Evaluation Score 
Calcification extension 
 
Occupied field of the 
section 
≤2/4 
>2/4  
0 
1 
Lipid core extension Occupied field of the 
section 
≤2/4 
>2/4  
0 
1 
Thin fibrous cap 
(Evaluated with ImageJ software) 
Thickness 
 
>200 um 
≤200 um 
0 
1 
Inflammation score:  
CD68 
CD3 
Tryptase 
Stained cells positivity 
0 to 3+ 
0 to 3+ 
0 to 3+ 
Sum of all markers  
<4+ 
≥4+ 
 
0 
1 
Neoangiogenesis (CD34) Vessels count in ROI 
(see text for details) 
<50mm2 
≥50mm2 
0 
1 
Vulnerable plaque if sum of the score ≥ 3 
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Table 2: First histological considerations to evaluate the vulnerability of the 
carotid plaque 
 
Inflammation infiltrate evaluation with ImageJ software, CEUS study 
An average of 5 fields per plaque transverse section was evaluated for each 
section; the area evaluated for each image was 0.12mm2 at a magnification 
of 10. The positivity for each antibody was arbitrarily semi-quantitatively 
scored as intense (3), moderate (2), low (1) or absent (0). To quantify the 
inflammation infiltrate, we summed the score positivity for CD3, CD68 and 
Tryptase. For a sample with an inflammation score lower than 4? and 
higher than or equal to 4?, we attributed, respectively, a value of 0 (low) or 
1 (high) inflammatory infiltrate. 
 
Neoangiogenesis evaluation with ImageJ software, CEUS study 
Neoangiogenesis was expressed as microvessel density, identified by 
CD34-positive immunostaining. The 5 images were converted to stack, 
transformed in montage, converted from colour images to 8-bit greyscale 
and scale was set (1600 px mm 1). The total area in square millimetre was 
evaluated for each stack, and then we set the lower and upper threshold 
values to select the stained area for CD34. For each stack, we counted the 
total number of microvessels, their diameter and the percentage of area 
occupied by vessels for each photograph. The mean microvessels’ density 
per section was expressed as a function of the total area analysed in the 5 
photographs (number of microvessels per mm2). 
 
Sequential double immunofluorescence assay on carotid plaque 
To investigate the expression of dPAPP-A and Osterix in the same cells, a 
double immunofluorescence assay was performed as described above. All 
washings were performed with PBS solution. Formalin-fixed paraffin-
embedded 5-um-thick tissue sections were dewaxed, rehydrated and antigen 
retrieval was performed as described above. Samples were then washed for 
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10 min. The sections were treated with goat serum (1:10, Sigma-Aldrich) in 
1% BSA in PBS for 30 minutes at RT and incubated first with anti human-
Nestin (1:400) in a moist chamber for 60 min, at 37°C. The samples were 
washed and labelled with a goat anti-mouse Alexa Fluor® 488 (1:250, 
Invitrogen Corporation, Camarillo, CA) in a moist chamber for 60 min, at 
37°C in the dark. After incubation and washing, slides were treated with 
donkey serum (1:10, Sigma-Aldrich) in 1% BSA in PBS for 30 minutes at 
RT and incubated with anti WT1 (1:1). Then, the slides were incubated 
with donkey anti-mouse Alexa Fluor® 647 (1:250, Invitrogen Corporation, 
Camarillo, CA) in a moist chamber for 60 min, at 37°C in the dark. Finally, 
after washing, the slides were mounted and nuclei counterstained with 
DAPI (Pro long anti-fade reagent, Molecular Probes, Milano, Italy). 
Negative controls were done by omitting the primary antibodies. After 24 
hours, samples were observed under a fluorescence microscope (Leica, 
DMI 6000 B) connected to a CCD camera to capture images. 
 
Vascular healthy tissue specimens and histopathological analysis 
Vascular specimens collected from multi-organ donors were kindly 
provided by the Cardiovascular Tissue Bank, Service of Transfusion 
Medicine, Policlinico S.Orsola-Malpighi of Bologna. At the end of organ 
procurement, a vascular surgeon is called to the Tissue Bank to grossly 
evaluate the status of the vascular specimens, and to exclude atheromasic 
plaques. Parts of those vascular segments without macroscopic lesions are 
therefore sent to our Pathology Unit for histopathological analysis, in order 
to verify their suitability for allograft transplant. Sixteen patients were 
prospectively selected and evaluated in one-year time length, 9 males and 7 
females, mean age 36.27±16.27 (range 16-58). In four cases two different 
vascular segments were retrieved, with a final number of 20 collected 
arterial specimens, from femoral artery (12 cases, 60%), abdominal aorta (4 
cases, 20%), iliac artery (2 cases, 10%) and renal artery (2 cases, 10%). 
Histopathological analysis with Haematoxylin and Eosin, Masson’s 
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trichrome stain and Weigert-van Gieson stain for elastic fibers, was 
performed in all cases by two dedicated pathologists to exclude tissue 
alterations due to bad preservation and/or misdiagnosed pathological 
conditions. Histology confirmed a normal architecture in all cases. In 
particular the adventitia was well preserved, and vasa vasorum were well 
identifiable in the adventitial fat tissue. Intimal endothelial cells were 
preserved and evaluable in 12 specimens. 
Immunohistochemical assay on healthy specimens 
Formalin-fixed paraffin embedded tissue sections were processed as 
described above. Sections were incubated with monoclonal antibodies 
against CD34, CD31, Nestin, dPAPP-A and SAA4 (see Table 1). WT1 
antibody detection was automatically performed with BenchMark XT® 
(Ventana Medical Systems, Inc, Tucson, USA) following the 
manufacturer’s instructions. 
 
Sequential double immunofluorescence assay on carotid plaque 
To investigate the expression of Nestin and WT1 in the same cells, a double 
immunofluorescence assay was performed as described above.  
 
Evaluation of vasa vasorum density with an ocular micrometer and 
morphology at IHC 
We decided to test an alternative and innovative method of count to 
evaluate microvessel density compared to the method used to count CD34 
positive vessels in carotid sections. Microvessel density was calculated 
through CD34 staining as a marker of both EPCs and mature endothelial 
cells, and CD31 staining as a marker of fully differentiated vascular and 
lymphatic endothelial cells. 
At 20x magnification we divided vascular adventitia in every IHC slide in 
1-mm2 fields, using an Olympus® ocular micrometer (1 length unit = 5 
mm, which means that an area of 100 x 100 units is equal to 0.25 mm2). 
The microvessel “density” per section was obtained by dividing the sum of 
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all vascular structures observed by the number of counted fields in the 
section of the total areas analysed in all fields (number of positive vessels 
per mm2). After microvessel density was determined, we counted the 
number of vascular structures expressing Nestin and WT1 in each field of 
all sections. Single-cell positivity and structure without a visible lumen 
were excluded from the count. 
Afterwards, we focused only on the “hot spots”, i.e. those areas particularly 
rich in Nestin- and WT1-positive structures. By means of ocular 
micrometer we sorted VV by diameter, and we classified them in ≤50 mm, 
50 to 100 mm and ≥100 mm, according to the classification used by 
Giannoni (Giannoni et al., 2009), which is very similar to the definition of 
“first order” and “second order” VV used by other authors (Kwon et al., 
1998; Mulligan-Kehoe et al., 2010). Finally, the different percentages of 
Nestin- and WT1-positive cells in the “hot spots” were counted in the three 
different groups of VV. 
 
Atheromasic tissue specimens and histopathological analysis 
 
Patients 
To repeat the same analysis performed above in healthy arteries, we 
analysed atheromasic plaque tissue retrieved from a series of consecutive 
patients during 2011 having the same characteristics described for the CEA 
study (symptomatic or asymptomatic carotid artery stenosis >=70%). 
Epidemiological data, neurological symptoms, vascular risk factors 
(hypertension, coronary-artery disease, chronic-obstructive pulmonary 
disease, dyslipidaemia, diabetes mellitus, current smoking and chronic-
renal failure) and current therapy (acetylsalicylic acid (ASA), anticoagulant 
and hydroxymethyl glutaryl coenzyme A reductase inhibitor) were 
recorded. Histological analysis and immunohistochemical assay of carotid 
plaque was performed as described above. Sections were incubated with 
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monoclonal antibodies against CD34, Nestin, dPAPP-A, CD68, SAA4 and 
WT1 (see Table 1).  
 
Evaluation of microvessel density with an ocular micrometer in carotid 
plaque at IHC 
In carotid plaque sections the CD34 positivity was limited to precise areas 
called region of interest (ROI). The counting is the same as the evaluation 
in healthy tissue. The microvessel “density” per section was obtained by 
dividing the sum of all vascular structures observed by the number of 
counted fields (ROI) in the section of the total areas analyzed in all fields 
(number of positive vessels per mm2). After microvessel density was 
determined, we counted the number of vascular structures expressing 
Nestin and WT1 in the same corresponding field (ROI) of all sections. 
Single-cell WT1 or Nestin positive structure without a visible lumen were 
named “dot” and evaluated separately as negative (=0) or positive (=1). The 
presence of large vessels structure with a “cavernous” morphology positive 
to WT1 or Nestin was signalled as negative (=0) or positive (=1). Positivity 
of macrophages or endothelial cells to dPAPP-A protein was noted as 
negative (=0), focal cells (=1) and diffuse (=2). 
Lipid core and calcification extension was evaluated as previously 
described (0=>no calcification or core, 1=>1/ 4 of the field occupied by 
calcification or core, 2=> 2/4, 3=> 3/4 and 4=> 4/4 all fields occupied). 
Phlogosis and neoangiogenesis presence were scored from 0 to 3 and the 
location was described as shoulder (1), cap (2), core (3) and diffuse (4). The 
presence (=0) or absence (=1) of complications, erosion and ulceration of 
the plaques lesions were signalled. By means of the ocular micrometer we 
evaluate the minimum and the maximum vessel diameter and fibrous cap 
thickness per section. Parameters are summarized in table 3. 
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Histological features Parameters Corresponding score 
Calcification extension 
Occupied field of the section 
 
1/4  
2/4  
3/4 
4/4  
 
1 
2 
3 
4 
Lipid core extension 
Occupied field of the section 
 
Idem 
 
Idem 
Thin fibrous cap 
 
Vessel diameter 
 
(Evaluated with an ocular micrometer) 
Thickness 
 
Diameter 
 
 
 
Min um 
Max um 
Phlogosis  (CD68) or Neoangiogenesis (CD34) 
description : 
Score 
 
Localization 
 
 
 
Stained cells positivity 
 
Shoulder 
Fibrous cap 
Core 
Diffuse 
 
 
0 to 3 + 
 
1 
2 
3 
4 
Vessel density for CD34, Nestin, WT1 
(Evaluated with an ocular micrometer) 
 
Vessels count (see 
text for details) 
Microvessels density 
(n°/mm2) 
“Cavernous” vessels: 
WT1 positive 
Nestin positive 
 
“Dot” vessels: 
WT1 positive 
Nestin positive 
 
 
 
Absence 
Presence (low signal) 
Presence (high signal) 
 
 
 
0 
1 
2 
 
Complications 
 
Ulceration or erosion 
 
 
Absence 
Presence 
 
 
 
0 
1 
 
dPAPP-A positivity:  
Macrophages cells 
 
Endothelial cells 
 
Negative 
Focal cells 
Diffuse 
 
0 
1 
2 
  
 
Table 3: Reviewed histological considerations to evaluate neoangiogenesis 
atheromasic carotid plaque. 
 
Evaluation of circulating markers’ concentration 
 
Measurement of circulating hsCRP and SAA. 
Serum hsCRP and SAA measurements were used as a surrogate marker of 
plaque embolic potential. Blood samples were collected 24 hrs prior to CAS 
and centrifuged at 1800 rpm for 10 min at room temperature (RT). Serum 
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hsCRP and SAA levels were analysed through nephelometric analysis 
(Image, Beckman Instrument); following hsCRP determination patients 
were divided into two groups: Class I, hsCRP<5 mg/l and Class II, 
hsCRP>5 mg/l. The threshold of 5 mg/l was chosen because higher serum 
hsCRP levels (>5 mg/l) were previously associated with vulnerable 
inflammatory plaque at histological evaluation (Garcia et al., 2003) and 
with complication risk during CAS (Gröschnel et al., 2007). The threshold 
of 10 mg/l was used for serum SAA levels according to the standard clinical 
reference range; higher values are associated to chronic infection, such as 
rheumatoid arthritis (Gillmore et al., 2001). 
 
VEGF and PAPP-A serological evaluation: ELISA assay 
Blood samples were collected 24 hrs prior to carotid revascularization in a 
clot activator tube (Vacuette, z-serum beads clot activator). Samples were 
placed at room temperature for 30 min to allow clotting, centrifuged at 
1800g for 10 min. Serum obtained was immediately aliquoted and stored at 
-80°C until analysis.  
VEGF serum levels were quantified with a Quantikine Human VEGF 
Immunoassay (Cat#DVE00, R&D systems, Inc, Minneapolis, MN, USA). 
The kit is a colorimetric solid phase Enzyme-Linked ImmunoSorbent Assay 
(ELISA) using a 96 wells microplate. Wells are pre-coated with a mouse 
monoclonal anti VEGF antibody. The optical density of each well was 
determined within 30 minutes at 450nm. A standard curve was built and 
GraphPad software generated a four-parameter logistic (4-PL) curve fit. 
The detection limit of the VEGF levels serum was less than 9.0 pg/ml.  
To evaluate the risk associated to higher levels of VEGF, a cut off of 
500ng/dl was chosen according to previous evaluations (Larsson et al., 
2002; Hasegawa et al., 2005). The cut-off was consistent with the 
manufacturer (R&D systems) normal control subject group. Elevated VEGF 
levels were defined as being greater than the 95th percentile value in the 
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normal control subject group described by R&D Systems. This resulted in a 
cut-off value for VEGF of 500 pg/ml. 
PAPP-A serum levels were quantified with the Active cPAPP-A Elisa 
(DSL-10-2760, DSL, Inc, Webster, TX, USA). The kit uses a microplate 
pre-coated with an anti-PAPP-A antibody. As described for the VEGF Elisa 
assay; the absorbance at 450 nm was read and a standard curve with a four- 
parameter logistic (4-PL) curve fit was created. The detection limit of the 
PAPP-A levels serum was less than 0.18 uUI/ml. 
 
NSE and PAPP-A mRNA expression level 
 
RNA Extraction from PAX gene tube 
For each patient 2.5 ml of peripheral blood were collected on PAX-gene™ 
Blood RNA Tubes (PreAnalytiX), stored at room temperature for a 
minimum of 2 hours, then at −20◦C for a minimum of 24 h, before 
processing or storing at −80°C. Total RNA was extracted using PAXgene 
Blood RNA kit (PreAnalytix) following the manufacturer’s instructions. 
RNA was eluted in RNAse free-water. For logistic problems PAX gene 
tube were not available in all cases; thus RNA from whole blood was 
extracted using also the Trizol method. 
 
Extraction with Trizol method 
Mononuclear cells from whole blood by Ficoll-Histopaque density gradient 
centrifugation (Ficoll Histopaque 1077, d=1,077 g/ml, Sigma Aldrich, ref 
10771) were isolated within 4 hrs from blood collection for optimal RNA 
extraction. The protocol of the manufacturer’s instructions was followed 
and count the cells were counted.  
Cells (1x106) were homogenized with 800 ul of Trizol reagent (TRI 
reagent, Ambion Cat #AM9738), collected in an Eppendorf tube and 
incubated for 5 min at RT. To obtain the phase separation, a proportional 
quantity of chloroform was added to the sample (0.2ml: 1ml trizol); the 
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sample are shacked vigorously for 15 seconds and incubated for 2 to 3 min 
at RT. It was left for 2 min in ice, centrifuged at 12000g, 15 min at 4°C. 
The centrifugation generates 3 phases: trizol in the lower, waste in the 
middle and RNA in the upper aqueous phase. The RNA phase was gently  
collected in a new Eppendorf. 500 ul of isopropyl alcohol (500ul: 1ml 
trizol) was added and 5 ul of glicogen (2ug/ul) was added on the wall of the 
Eppendorf. Samples were then incubated at RT for 10 min, centrifuged at 
12000g for 10 min, 4°C to allow RNA precipitation. Surnatant was 
discarded and RNA pellet was washed with 75% ice ethanol (1ml: 1ml 
trizol), then centrifuged at 7500g for 5 min, air dried for 20 min and 
dissolved in 15 ul of RNase free water.  
Finally eluted RNA (from PAX or Trizol method) is heated 5 min at 65°C 
(in order to denature RNA and to inactivate RNases) and immediately 
placed in ice. RNA quality and concentration were assessed by measuring 
the A260/280 and A260/230 using a Nanodrop ND-420 (Nanodrop 
Technology). RNA was stored at −80◦C until used. 
 
Reverse transcription assay 
Reverse transcription assay was performed using 1 ug of starting total RNA 
quantity per 25 ul of mix, following the manufacturer’s protocol (High 
capacity cDNA Archive kit, Applied Biosystem). The cDNA was stored at 
– 20 °C until RT-PCR were performed.  RT-PCR was carried following 
MasterMix Taqman Protocol (TaqMan Univ PCR MasterMix, Applied 
Biosystem). 4ul of cDNA was amplified using specific primers for NSE, 
PAPP-A and betaActin described in the table below (Taqman Gene 
Expression Assay, Applied Biosystem) in the RT-PCR mix. 
 
MIX qPCR 1 sample 
Master mix Taqman  10 
Probe NSE/betaACT or PAPP-A  1 
H20 5 
cDNA  4  
Vol TOT per well 20ul 
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Reactions were run on ABI PRISM 7900HT Sequence Detection System 
(Applied Biosystems). Cycling conditions were as follows: 10 min at 95◦C, 
40 cycles at 95◦C for 15 s and 60◦C for 60 s. Each assay was carried out in 
triplicate and the transcription level was normalized using beta Actin as a 
reference gene. A standard curve (used as calculation method) with five 
dilutions of cDNA (Clontech, Palo Alto, CA) obtained from normal healthy 
human brain was included in each respective PCR run. Calibration curves 
were constructed by plotting the threshold cycle versus logarithm of the 
relative concentration. 
 
Statistical analysis 
Continuous variables were expressed as a mean ± standard deviation (SD), 
categorical variables by relative and absolute frequencies. All correlations 
were first analyzed with a multiple regression. Analyses of differences 
between two groups were performed with Fisher’s exact test for categorical 
variables and with unpaired Student’s t test or Mann-Whitney U test for 
continuous variables. Analyses of differences between more than two 
groups were performed with the Kruskal-Wallis one way ANOVA test. The 
value of p<0.05 was considered significant. Goodness of fit in binary 
regression model was tested with the Hosmer-Lemeshow analysis. 
Statistical tests were performed using SPSS® 13.0 for Windows® computer 
software (SPSS, Chicago, Illinois, USA).  
To analyse and represent basic biostatistics, curve fitting and scientific 
graphing of biological data we used Prism 5® software (GraphPad 
Software, Inc). We used the non-parametric Spearman correlation 
coefficient. The best way to interpret the value of r is to square it to 
calculate r2. Thus for the graphical representation we used a linear 
regression with an r2 value from the Pearson correlation coefficient.  
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RESULTS 
 
A total of 84 patients were enrolled from January 2009 to December 2011. No peri-operative 
complications (neurological events, myocardial infarction, death) were recorded in neither 
group. Epidemiological data, neurological symptoms, vascular risk factors and current 
therapy of all patients submitted to CEA or CAS were recorded in our database. 
 
CAS, biomarkers and cerebral lesions 
 
Patients CAS. 
Thirtyfour patients either symptomatic or asymptomatic were included in the study. In two 
cases the CAS procedure was aborted due to technical difficulties and the stent was not 
deployed. The filters were positioned, subsequently removed and utilized as a control 
specimen. Mean hsCRP, SAA, VEGF, PAPP-A and HDL serum levels are listed in the 
table1.  
 
 hsCRP SAA VEGF PAPP-A Col Tot LDL TG HDL 
Mean 15.54±20.36 40.39±8.89 566.4±304.00 1.22±1.26 183.4±32.5 111.7±19.51 134.6±36.25 43.14±8.86 
 
Table 1: Mean serum levels of the studied proteins 
 
Drug therapy CAS 
All patients were medicated with aspirin 100 mg and clopidogrel 75 mg for 3 days before 
and one month after the procedure. Hydroxymethyl glutaryl-coenzyme A-reductase inhibitor 
(statins) therapy was used by 12 patients. No significant difference was seen in filter 
percentage of occluded pores (PO), area covered by debris (SI) and SEM evaluation between 
patients with or without anticoagulant therapy, antiaggregant therapy or statins therapy (data 
not shown). 
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Distribution and description of the material covering the filter 
 
Filter analysis by light microscopy. 
All filters showed the presence of a substantial amount of debris at macroscopic observation. 
Two of them had extensive deposits of vitreous, yellowish lipid-like material that was 
dissolved after histological processing (Fig. 1A). Microscopic debris were detected in all 
filters, with a mean percentage of surface involvement (SI) of 29.33%±8.1 and pore occluded 
(PO) of 27.30%±9.5; control filters showed both a lower SI, 4.15%±2.3, and PO, 0.50%±0.3, 
compared to filters of treated patients (p<0.05). As we noticed that same statistical 
correlation in all analysis between PO and SI%, the 2 evaluations were considered 
interchangeable.  
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Figure 1: Left panel: a filter used during CAS (A, scale bar 1mm) and the corresponding 
scanning electron microscopy showing details of the point with accumulation of embolic 
material (B, scale bar 100 µm). Hematoxylin-eosin staining of a plaque fragment removed 
from the filter point (B, insert; magnification 40x). Distribution of embolic material (% SI) in 
three different zones of the filter: distal (zone C), medial (zone B) and proximal (zone A) 
(graphic C). Right panel: surface filter showing a variety of cells ranging from red blood 
cells, acanthocytes, aggregates of dendritic, activated platelets (white arrows; A, scale bar 5 
µm) and fully spread platelets (white arrows; B, scale bar 10 µm). 
 
 
 
Distribution of the material was heterogeneous along the filter membrane with a significantly 
higher SI (37%± 9.00) at the tip of the filter (zone A) compared to the middle zone (zone B; 
28%±7.7) and distal zone (zone C; 23%±8.3) (Fig. 1C). Plaque fragments were commonly 
seen at the tip of the filter (Fig. 1A, B). Hematoxylin-eosin staining revealed that the type of 
material removed from the paraffin embedded filters was composed by thrombo-embolic 
debris, acellular material, cholesterol clefts and atheromatous plaque fragments (Fig. 2). 
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Figure 2: Histological images of debris recovered from the entire filter membrane showing 
necrotic-lipid core (A and C; FC) and fibrous cap (B; NC) fragments; D) higher 
magnification of panel C showing amorphous and acellular material rich in cholesterol clefts 
(arrows). Scale bars: A, B, C = 100 µm; D = 5 µm. 
 
 
Filter analysis by scanning electron microscopy. 
To clarify the composition and the mean size of debris adherent to the inner surface part of 
the filter, devices were analysed through SEM and histological analysis. Unlike control 
filters, visibly clean, all areas of the filter were covered with debris ranging from 30µm to 2 
mm. All filters were covered with an amorphous film, i.e., biofilm, of protein composition 
typical for all biomaterial. Pores of 100 µm diameter were occluded by clumps of red blood 
cells (RBC), embolic and plaque fragments (Fig. 3). SEM also revealed the presence of 
activated platelets with dendritic and spread morphologies (not shown). 
No differences were found in volume and composition of embolic debris between patients 
with homogeneous and dishomogeneous plaque (data not shown). 
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Figure 3: Representative scanning electron microscopic images of thromboembolic 
materials captured by the filter surface (A, scale bar 25 µm; B, scale bar 40 µm). Details of 
plaque fragment trapped at the filter’s tip (C, scale bar 500 µm; D, scale bar 100 µm) 
 
 
Markers levels pre-procedural, amounts of debris and cerebral lesions post-procedural 
 
Patients with hsCRP>5mg/l had a greater percentage of PO (and SI) compared with lower 
levels of hsCRP (32.78%±11.41 vs. 23.9%±6.7, p=0.0019 (33.3%±7.7 vs. 25.4%±7.0, 
p=0.07 respectively) (Fig. 4 left upper graph).  
According to the type of plaques, patients with dishomogeneous plaque had a significantly 
higher PO vs those with homogeneous plaque (38.68%± 7.1 vs. 24.06%±5.6 respectively, 
p=0.036) (Fig. 4 right upper graph). Patients having higher hsCRP level (≥5mg/l) and 
dishomogenous plaque had a greater number of occluded pores and a major % of surface (SI) 
covered with debris (35.7%±11.7 vs. 19.9%±6.7, p=0.049 and 33.3%±7.7 vs. 25.4%±7.0, 
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p=0.04) respectively compared to patients with homogenous plaque and lower hsCRP 
(<5mg/l) (Figure 4A, B).  
 
 
 
 
Figure 4: hsCRP level, plaque type and filter protection. Percentage of PO and SI for 
hsCRP<5mg/l and for hsCRP>5mg/l levels. Percentage of PO (A) and SI (B) in patients with 
hsCRP<5mg/l homogenous or hsCRP>5mg/l and dishomogenous plaque. 
 
 
For patients with high SAA (>10mg/l) and VEGF (>500pg/ml) values we found filters with 
an increased number of pore occluded (PO) by debris.  (Fig 5, SAA: 22.20±6.90 vs 
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35.94±13.52%, p=0.023 and VEGF: 22.45±5.68 vs 37.09±11.06%, p= 0.0047). High 
percentage of occluded pores was also associated with high PAPP-A levels and low HDL 
levels (trend, fig. 5). 
 
 
          
Figure 5: SAA, VEGF. PAPP-A, HDL and percentage of occluded pores of the filter 
protection 
 
Patients presenting neurological symptoms before the CAS procedure had an increase of the 
amout of debris covering the filter membrane (Fig 6, 22.70±6.9 vs 35.52±6.95%).  
After the stenting procedure, ischemic asymptomatic cerebral lesions were observed in all 
patients. The median number of cerebral lesions was 22 range 0-2550 and the median 
volume was 500 range 0.0001-12043mm3. Patients with more than 30% of the filter area 
covered by embolic debris showed a higher number of total cerebral lesions post CAS (Fig 6, 
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15.7±7 vs. 3.4 ±2.1, p=0.03). Patients with hsCRP ≥ 5mg/l showed a higher number of total 
cerebral lesions (2.5±1.64 vs 17.5± 5, p=0.01) compared to patients with lower hsCRP levels 
(OR 2.6, CI 1.005-6.8) (Fig 6). hsCRP ≥ 5mg/l is also associated to the volume of cerebral 
lesions ≥1000 mm3 (OR 3.9, C.I. 1.1-13.7, not shown).  
 
 
Figure 6: Cerebral lesions post-procedural and hsCRP levels pre-CAS. In the RMx imaging 
the circle indicates a cerebral lesion. 
 
Patients who had SAA > 10mg/l showed a significave increase of the number of total 
cerebral lesions compared to patients with lower SAA levels before the procedure (3.4±1.14 
vs 18.2±6.35, p=0.012) (Fig 7). Serological values of SAA> 10mg/l before the CAS 
procedure is also associated to a major volume of cerebral lesions (3253.12±567 vs 
513.02±202 mm3, p=0.004). Moreover,a perfect positive linear correlation was observed 
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between the volume of cerebral lesions and SAA serum level pre CAS (Figure, r2=0.962) 
(Fig 7). 
 
 
Figure 7: Cerebral lesions post-procedural and SAA levels pre-CAS. RMx showing cerebral 
lesions in 2 different’s loci. 
 
NSE mRNA and mRNA PAPP-A expression levels were not associated to the presence of 
cerebral lesions. However circulating NSE mRNA levels in blood increased up to 4 times 
with the increase of SAA and hsCRP serum levels (Fig 8). In patients submitted to CAS 
procedure we found an increase of 32% of the expression of NSE mRNA compared to CEA 
procedure. 
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Figure 8: NSE mRNA expression level and inflammation markers 
 
 
Identification of plaque vulnerability in patients submitted to CEA 
 
Patients 
Fifty-two patients either symptomatic or asymptomatic were enrolled for the CEA study. 
Mean hsCRP, SAA, VEGF, PAPP-A and HDL levels are listed in table 2. 
 
 hsCRP SAA VEGF PAPP-A Col Tot LDL TG HDL 
Mean 4.035±2.72 12.8±.1.3 617.4±200 1.5±1.16 163.4±33.5 103.8±27.51 102.3±26.5 50±8.44 
Table 2: Mean serum levels of the studied proteins 
 
hsCRP levels were significantly higher in symptomatic patients compared to asymptomatic 
ones: 19.9±34.2 vs. 4.3±3.2 mg/l, p=0.007. The same relation was observed for VEGF; 
serum levels were 623.6±133.8 pg/l in symptomatic and 443.2±161.9 pg/l p=0.04, in 
asymptomatic patients. 
We remind that plaques, in this first part of the study on CEA, were evaluated for 5 
histological parameters; microvessels density, fibrous cap thickness, inflammation, 
calcification and lipid core area. The sum of these 5 parameters (0-5) defines the histological 
plaque vulnerability. 
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CEUS evaluation, inflammation and plaque vulnerability 
 
Among the 52 CEA patients, a group of 22 patients was submitted to contrast-enhanced 
ultrasonography (CEUS) analysis. dB-E ranges from 2 to 7.8, mean 4.85±1.9. No statistically 
significant differences were identified for demographic characteristics, vascular risk factors 
or current therapy (not shown).  
It was seen that patients with ischaemic neurological symptoms pre-CEA (stroke, TIA or 
amaurosis fugax) had significant higher carotid dB-E compared with asymptomatic ones 
(7.40±0.5 dB-E vs. 3.5±1.4 dB-E respectively, p=0.006). In particular the presence of an 
ipsilateral embolic lesion on preoperative CT scans was significantly correlated with higher 
dB-E on CEUS compared with patients with negative cerebral CT scan (5.96±1.5 dB-E vs. 
3.0±1.0 dBE, respectively, p=0.01).  
At histological evaluation, the presence of high inflammation infiltrate in the carotid plaque 
specimens was related to higher dB-E at CEUS evaluation, compared with specimens with 
lower inflammation. Ten patients had a score inflammation of 4-5 with a dB-E of 7.4±1.2 
and 12 patients, score 1-2, had a dB-E of 3.2±0.9 (p=0.03). 
Microvessels were identified in the medial border of the lipid core, within the cap, within the 
lipid core, within the intima and in the shoulder. The percentage of number of vessels per 
region was 59%in the shoulder, 26% in the cap and 15% in the core. We observed that an 
elevated vessel density on plaque specimens (>50mm2) corresponds to a higher dB-E 
(<50mm2: 2.5±0.7 dB-E vs 50mm2: 5.5±1.2 dB-E, p=0.04). An increase of dB-E was also 
noticed in patients presenting a fibrous cap <200um (<200um: 5.96± 1.5 dB-E vs >200um: 
3.0± 1 dB-E, p=0.01). Finally, plaques with a vulnerability score of 5 had an increase of the 
dB-E compared to patients with a vulnerability score of 1 (7.6±0.2 vs. 2.5±0.6, p=0.001) 
(plaques scored 2 had a dB-E of 4.6± 0.8; scored 3 in none; scored 4 had a dB-E of 7.1±0.5). 
The dB-E levels were significantly different between vulnerability groups (p=0.001) (Fig 8).  
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Figure 8: dB-Enhancement evaluation of plaque vulnerability score. Differences between 
groups are statistically significant at ANOVA analysis (p=0.001). 
 
 
VEGF, hsCRP serum levels and histological plaque vulnerability  
 
All 22 carotid plaque specimens were suitable for the histological evaluation. Inflammation 
markers were present in all carotid specimens analysed with different grade of staining (Fig. 
9 A-D): CD68, marker of macrophages, was highly expressed in all carotid plaques sections 
compared to mast cells followed by lymphocytes, as shown in figure 9E (p<0.05).  
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Figure 9: Characterization of plaque vulnerability in the CEA procedure. To evaluate 
inflammatory infiltrate carotid plaque sections were immunostained with CD3 (A, 
lymphocytes in the shoulder area), CD68 (B, macrophages in the fibrous cap), Tryptase (C, 
mast cells in the fibrous cap). Microvessels in proximity of the core stained with CD34 (D). 
Distribution of grade of staining for each marker (E). 
 
Patients with vulnerable plaques (vulnerability score 3 to 5) had higher hsCRP and VEGF 
serum levels compared with patients with non vulnerable plaques (score 0 to 2) (hsCRP: 
21.3±24.2 mg/l vs. 3.0±1.7 mg/l, p=0.004 and VEGF: 660.8±284.0 pg/ml vs. 429.9±262.9 
pg/ml, p=0.01). The presence of inflammation infiltrate in the carotid plaque specimens was 
related to higher dB-E at CEUS evaluation, compared with specimens with no inflammation 
(7.4±1.2 dBE vs. 3.2±0.9 dB-E, respectively, p= 0.03) (not shown). 
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Moreover patients with pre-operative neurological symptoms presented high score of plaque 
vulnerability (score 2 to 3) at histological analysis (p=0.02). HsCRP >5mg/l was associated 
with the presence of vulnerable plaques with Odd Ratio (OR) 2.5, Confidential Interval (CI) 
95%1.1-5.5, p=0.01; the presence of VEGF>500 pg/l was associated with the presence of 
vulnerable plaques with OR 3.0, CI 95%1.1-7.7, p=0.01. 
 
Thin fibrous cap 
Neurological symptoms were detected in 57.14% and 67% of them presented erosion and/or 
ulceration of the plaque surface. Neurological symptoms were also associated positively to 
the thickness of the fibrous cap (TC negative: 207.9±72.07um vs TC positive 98.63±52.67) 
(Fig 10). The fibrous cap was thinner in patients with higher level of VEGF (p=0.0001 
r2=0.5601), NSE mRNA expression level (p=0.032, r2=-0.711) and a trend was observed for 
the level of triglycerides. Inversely patients with major level of HDL presented a thicker 
fibrous cap (trend) (Fig 11). 
 
 
 
Figure 10: Association between fibrous cap thickness of the plaque and the presence of pre-
operative neurological symptoms in patients submitted to CEA. 
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Figure 11: Correlation between the thickness of the fibrous cap and VEGF, NSE mRNA 
expression level, triglycerides and HDL blood level.  
 
 
 
Vascular healthy tissue specimens and histopathological analysis 
 
CD31 and CD34 
The mean number of CD31-positive vascular structures in the adventitia of the 20 cases was 
181.60±94.52 (median 152, range 67-425), the mean counted fields were 12.86±4.23 mm2 
(median 12, range 6-21 mm2), the mean final “density” of CD31-positive structures was 
13.63±3.50/mm2 (range 8.11-22.67/mm2, Fig. 1A). The mean number of CD34-positive 
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vascular adventitial structures was 146.30±72.27 (median 133, range 34-329), the mean 
counted fields were 11.53±3.98 mm2 (median 11, range 4-18 mm2), the mean final 
“density” of CD34-positive structures was 12.20±3.04/mm2 (range 7.68-20.89/mm2, Fig. 
12A). The mean ratio between CD34 and CD31 “densities” was 0.94±0.24, very close to 1.  
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Figure 12: Immunohistochemistry results. A) Histogram representing mean densities of 
positivity expressed as number of positive vessels/mm2 of CD31, CD34, Nestin and WT1; 
B) Scatter plot illustrating the distribution of the Nestin/CD31 and WT1/CD31 ratios in all 
cases (see text for details); C) Histogram with the percentage of Nestin- and WT1-positive 
cells in the three groups of vasa vasorum sorted by diameter. Right panel; an example of 
immunohistochemical pattern of positivity for CD31 (upper), Nestin (center), and WT1 
(lower) in small-sized vessels (25x magnification). 
 
Nestin and WT1 
The mean number of Nestin-positive vascular structures in the adventitia of the 20 cases was 
117.10±59.13 (median 114, range 19-242), the mean counted fields were 12.83±4.20 mm2 
(median 14, range 5-19 mm2), the mean final density of Nestin-positive structures was 
8.90±3.04/mm2 (range 3.04-15.87/mm2, Fig. 12A). The ratio between Nestin density and 
CD31 density ranged from 0.34 to 1.29, with a mean Nestin/CD31 ratio of 0.69±0.26, which 
briefly means that a mean of 69% of CD31-positive vessels showed concomitant positivity 
for Nestin as well (Fig. 12B). 
The mean number of WT1-positive adventitial vessels was 105.85±51.63 (median 95, range 
23-209), the mean counted fields were 13.24±3.82 mm2 (median 14, range 2-20 mm2), the 
mean final density of Nestin-positive structures was 7.98±3.04/mm2 (range 2.88-14.73/mm2, 
Fig. 12A). The ratio between WT1 density and CD31 density ranged from 0.25 to 1.27, with 
a mean WT1/CD31 ratio of 0.63±0.27, which means that a mean of 63% of VV showed 
concomitant positivity for WT1 and CD31 (Fig. 12B). 
As expected, the ratio between Nestin and WT1 “densities” is very close to 1:1. Indeed the 
mean Nestin/WT1 ratio in all 20 cases was 1.15±0.25. 
 
Comparison between IHC and vessel morphology 
Since not all VV showed positivity for Nestin and WT1, we focused on the “hot spots”, i.e. 
the areas of major positivity. Of note, Nestin-positive and WT1-positive vascular structures 
of ≤50 µm in diameter were positive for those antibodies in the large majority of cells (95% 
and 90% of cells respectively for Nestin and WT1). Positive VV with diameter ranging from 
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50 to 100 µm had a mean of 84% and 77% of Nestin- and WT1-positive cells respectively. 
Positive vessels ≥100 µm in diameter expressed only 61% and 57% of Nestin and WT1 
respectively (see also Fig 12C). 
There is an increase in Nestin and WT1 expression, in terms of number of positive cells, and 
it is inversely correlated to the size and calibre of the micro-vessels. In particular in this 
study we observed higher positivity for Nestin and WT1 in small arteries (recognizable by 
the muscular layer), less than 50 µm in diameter, especially in “nests”, relatively distant from 
vascular media, in which several small arteries were visible together with small veins of 
similar size and peripheral nervous structures (Fig. 12 and 13). Conversely, vessels of more 
than 100 µm in diameter, both arteries and veins, were generally negative for Nestin and 
WT-1, or showed only few scattered positive cells. 
 
Figure 13: A representation of a first-order vasa vasorum, its second-order vasa vasorum, 
and a hypothetical “hot spot” in the branching. Inserts A,C, E show the histological 
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appearance of each level (Haematoxylin-Eosin stain, 10x magnification), inserts B, D, F 
show Nestin immunoreactivity (10x magnification). 
 
 
Localization of Nestin and WT1 at immunofluorescence 
Since in the IHC assay we noticed that the Nestin expression pattern closely resembled the 
pattern of WT1 and the ratio between Nestin and WT1 “densities” is very close to 1:1, we 
investigated by double immunofluorescence whether these two proteins had an overlapping 
localization. Nestin and WT1 signals co-localized in the endothelial cells from adventitial 
VV, including the “hot spots”. WT1 signal was strongly expressed by endothelial cells 
mainly in vessels of ≤50 µm in diameter. The expression was confined in the perinuclear and 
nuclear area (Fig. 14A), but a cytoplasmic pattern was also observed (Fig 14D). Nestin 
expression was restricted to the cytoplasm (Fig. 14B and C). The merge of WT1 and Nestin 
revealed that they were mostly expressed in the same cell population (Fig.14E) and, 
surprisingly, cytoplasmic expression of WT1 overlaps nestin expression. This phenomenon 
was mainly observed in endothelial cells from vessels of >100µm in diameter. 
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Figure 14: Double-label immunofluorescence micrographs representing WT1 (red) detectable in the 
nucleus of vessels <50 um (A) or in the cytoplasm of vessels with a diameter >100 um (D) and 
Nestin (green), detectable only in the cytoplasm (B, C). The merged image (E) shows the 
colocalization in the cytoplasm of Nestin and WT1 proteins in a vessel of > 100um. Nuclei (blue) 
were counterstained with DAPI. Scale bars: 25 um. 
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Vascular atheromatous tissue specimens and a new histopathological analysis: a 
neoangiogenesis study 
In this analysis the number of positive vessels was evaluated in the same positive region of 
interest for each markers. To simplify the results presentation we express one field as 1 mm2 
(corresponding in the ocular micrometer to four fields of 0.25um2). 
 
CD34, Nestin and WT1 
The mean number of CD34-positive vascular adventitial structures in atherosclerotic plaques 
of the 23 cases analysed was 100.65±68.68 (median 87, range 11-283), the mean counted 
fields were 2.35±1.72 mm2 (median 2, range 0.25-8.25 mm2), the mean final “density” of 
CD34-positive structures was 43.27±14.68/mm2 (median 42.28, 22-88.56/mm2, Fig.).  
The mean final “density” of Nestin-positive structures was 32.68±12.65/mm2 (median 30.84, 
12-58/mm2, Fig 15). The mean final “density” of WT1-positive structures was 
17.95±9.80/mm2 (median 17.00, 4-40/mm2, Fig 15.).  
 
Neoangiogenesis histological score (0-3) was perfectly linear with the n° of fields evaluated, 
n° of positive cells and density of each markers (CD34-WT1-Nestin, data not shown). All 
measurements were highly repeatable; the number of fields and the number of positive cells 
counted for each marker were highly comparable (Fig 15). Neoangiogenesis score was 
strongly associated to the degree of inflammation in the atheromateous plaque (p=0.016, data 
not shown). 
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Figure 15: Graphical representations of the parameters studied for neoangiogenesis analysis 
in atheromateous palques. 
 
Nestin and WT1 “dis-correlation” 
In atheromateous arteries the Nestin expression pattern didn’t match the pattern of WT1 as in 
healthy arteries. WT1 signal intensity was weaker in atheromateous vessels (Fig 16).  
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Figure 16: Example of immnostaining for each marker. Magnification 25X 
 
 
The ratio between Nestin and WT1 “densities” is not close to 1 but to 0.5 (Figure 17). In 
healthy arteries 90.7% of vessels positive to Nestin expressed WT1, in atheromateus plaques 
only 55.9% of Nestin positive vessels expressed WT1 (p<0.05). There is no significative 
difference between Nest/CD34 density ratio in healthy and atheromateous arteries; in both 
cases the ratio is close to 0.8. There was a significative difference of density ratio 
CD34/WT1 between healthy and atheromateous plaques; in healthy arteries 67.2% of vessels 
positive to CD34 expressed WT1, in atheromateus plaques only 43.8% of CD34 positive 
vessels expressed WT1 (p<0.05) (Fig 17).  
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Figure 17: Density ratio of each markers. The arrow represents the decrease of ratio density 
between WT1 and Nestin. 
 
The immunohistochemical analysis also revealed different patterns of CD34 staining. 
Microvessel morphology ranged from small regular vessel, flattened, irregular lobulate-
shaped vessel or big angiomatoid vessel (Fig 18). 
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Figure 18: CD34 immunostaining of intraplaque microvessels. A) Small, regularly-shaped 
microvascular pattern; B) Cavernous, angiomatoid microvascular pattern. 
 
Dots vessels 
We noticed in 7 lesions (30.4% of cases) the presence of small vessel composed by one 
single endothelial cell with or without a lumen. The presence of dots vessels in 
atheromateous lesions was significantly associated to neoangiogenesis score (6 cases having 
a score 3, p=0.004). Dots positive areas are diffuse among the lesion; 6 cases correspond to a 
diffuse neoangiogenesis (6 cases with a score 4, p=0.007, not shown). Plaques containing 
dots structure also correspond to lesions with a higher number of fields and number of 
positive vessels to CD34+, Nest and WT1 (p<0.05). Five cases (71.42%) had a strong 
positivity (2+) to Nestin while none dots was WT1 positive (Fig 19). A weaker intensity of 
staining (1+) was observed in one cases for Nestin and 4 cases for WT1. Dots didn’t express 
at all Nestin in one cases and neither WT1 in 3 cases. The presence of dots vessels was also 
associated to the absence of macrophages postive to dPAPP-A (trend p=0.06) and to an 
increase of SAA serum levels (6.82±2.3 vs 90.03±48 mg/l, trend p=0.06) (Fig 19). 
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Figure 19: Association between the presence of dot vessels and neoangiogenesis (all p 
value<0.05 Mann-Whitney U and Wilcoxon W tests). Fields are expressed in 0.25um2 for a 
better graphical representation. Images of dots vessels, 10 X magnification. The right bottom 
graph represents the relation between SAA serum levels and dots presence in plaques. 
 
 
Complications in atheromateous plaques 
Calcification was more frequent in female; 85.7 % of female presented a calcified score of 2 
or 3. Only 42.85% of males had high calcification score (p<0.0001).  
Complications and erosion of the atheromateous palques were related to age, symptomatic 
patients, to the presence of neurological symptoms and to TIA. After 75 years, 91% of the 
patients presented plaques with complications that increased up to 30% compared to patients 
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under 75 years (p=0.0397). The main complication involved was the erosion of the plaque 
(Figure 20). Symptomatic patients presented major complications of the carotid plaques 
(14.28% vs 57.14%, p=0.015). The same relationship was seen between patients who 
underwent a TIA and the presence of complicated plaques (p=0.005).  
 
 
Figure 20: Association between plaque structure, age and symptoms. 
 
Calcified nodules  
We noticed the presence of plaque with calcified nodules in 7 cases. So we decided to 
compare histological, serological and clinical characteristics of these seven cases to another 
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group of 7 atheromateous plaque without calcified nodules and with a low calcification score  
(0 or 1). No differences were found for age, gender, AHA lesion classification, diabetes, 
IRC, ASA, statine terapy, PAPP-A or VEGF serum levels, symptoms, TIA, presence of 
neurological symptoms and ipertension (Table 3).  
 
 No nodules 
(calcification 
score 0-1) 
7 
Calcified nodules 
7 
p value 
Age  
70.86±8.9 
 
69.75±10.89 
 
ns 
 Gender 
Male 
Female  
 
5 
2 
 
6 
1 
 
ns 
Neurological symptoms 
Yes  
No  
 
 
3 
4 
 
 
5 
7 
 
 
ns 
Dislipidemia 
Yes 
No 
 
6 
1 
 
6 
1 
 
ns 
Diabetes 
Yes  
No 
 
2 
5 
 
1 
6 
 
ns 
Smoke 
Yes  
No   
 
3 
4 
 
1 
6 
 
p<0.05 
Chronic-obstructive 
pulmonary disease  
Yes  
No  
 
 
3 
4 
 
 
1 
6 
 
 
ns 
Stenosis  87.8%± 9.1 76.75 ns 
Hydroxymethyl glutaryl 
coenzyme A reductase 
inhibitor user 
Yes  
No  
 
 
 
5 
2 
 
 
 
5 
2 
 
 
 
ns 
 
VEGF pg/ml 366.9 ±200 376.2 ±210 ns 
hsCRP mg/l 2.86 ±1.19 14.19 ±6.16 p<0.05 
SAA mg/l 4.32 ±1.18 31.44±19.9 p<0.05 
PAPP-A  1.51±1.87 1.16±1.35 ns 
 
Table 3: Clinical characteristics of patients presenting a plaque with calcified nodules. 
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Significative differences were noticed for smoker, histological and serological markers 
levels, lipid core area and complications of the lesions (erosion and/or ulceration). Data are 
summarized in figure 21.  
Patients with calcified nodules had a decrease of 42.11% of phlogosis histological score 
compared to atheromateous plaque (score 11+ vs 19+, p<0.05). Serum inflammation proteins 
levels were also decreased; mean hsCRP and SAA in patients presenting calcified nodules 
were respectively 2.86±1.19 mg/l and 4.32±1.18 mg/ml vs 14.19±6.16 and 31.44±19.90 
mg/ml in atheromateous patients (p=0.024). Only 57% of the calcified nodules had a high 
lipid core area score (2-3) compared to 95% in atheromateous plaques. (p=0.02). 
The presence of complications was seen in 83% of the atheromateous plaques while only 
17% of the calcified nodules presented complications of the plaque structure (p=0.02). 
Compared to atheromaterous plaque, immunohistochemical analysis showed an intense 
positivity to dPAPP-A of the area surrounded calcified nodules. The immunofluorescence 
analysis revealed that dPAPP-A was negative or weakly expressed in healthy arteries (data 
not shown).  
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Figure 21: Summary of the significatives differences between patients presenting an 
atherosclerotic plaque with or w/o calcified nodules (Fisher test, p<0.05). 
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DISCUSSION 
 
 
 
Cerebral lesions risk and serological markers levels 
 
The risk of embolization from carotid plaque is of paramount importance 
both in indication to revascularization and during the carotid endovascular 
procedure. However, methods to objectively identify this risk are presently  
not available. Several methods have been suggested, (i.e. GSM, Magnetic 
Resonance imaging, Computed Tomography etc.) In fact no study has 
correlated the amount of embolic debris in CAS procedure and serological 
markers such as CRP. In this study we examined filters obtained by the CAS 
procedure, evaluating the amount and the pattern of debris, indicative of the 
vulnerability of the plaque treated. According to our data, not all plaques 
behave similarly; patients with CRP above 5 mg/l, SAA above 10 mg/l and 
VEGF above 500 pg/ml showed a significantly increased number of pores 
occluded (PO), indicative of debris greater than the size of pore filter, i.e., 
100 µm. As know HDL removes excess cholesterol from walls’ arteries; in 
fact patients showing higher HDL blood levels presented a filter with lower 
PO and thus less accumulation of thromboembolic material on the 
membrane.  
These findings and their correlation with the embolic potential of the plaque 
is supported by the relationship existing with echographic characteristics of 
the plaques: dishomogenous plaques showed a significantly greater 
percentage of both pore occluded, which further supports the clinical findings 
of their higher embolic potential. In this sense, it is not surprising that 
patients with elevated CRP and dishomogenous plaque had an even greater 
percentage of PO. Ultrastructural appearance of the debris and histological 
analysis showed features consistent with the plaque origin of the emboli; it 
should be outlined that in the CAS technique employed in this study, filters 
are opened only during stent deployment and dilatation. We can therefore 
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reasonably exclude other possible origins of embolic material, as confirmed 
by the analysis of the control filters. Moreover, the amorphous material 
retrieved from the filter membrane originated from dislocated fragments of 
the necrotic core during the procedure. These results confirm the data 
obtained in previous studies evaluating the nature of embolic debris captured 
during the procedure (Angelini et al., 2002; Hayashi et al., 2009). 
An increase of post procedural cerebral lesions was detected in patients 
having hsCRP >5 mg/l and SAA >10 mg/l values. During the CAS procedure 
fragments of plaque get detached and pass through the pores of the filter 
protection causing an increase of cerebral lesions. The number and the 
volume of cerebral lesions are predictable by hsCRP and SAA serum levels 
before the procedure.  
Thus high hsCRP, VEGF and SAA levels are correlated with the amount of 
embolic material seen in cerebral filters demonstrating the relationship 
between carotid plaque structure, inflammation and the embolic potential in 
CAS. 
 
 
Identification of vulnerable plaque 
CEUS with dB-E can be used as a marker for vulnerable plaque. dB-E was 
associated significantly with different histological parameters of the 
atherosclerotic plaque; thinner fibrous cap, greater inflammatory infiltrate 
and greater microvessels’ density. An increase of dB-E was also associated to 
either symptomatic patients or to the presence of preoperative ipsilateral 
embolic lesions. Correlated to the recognition of vulnerable plaque, we 
observed that patients having neurological symptoms pre-operatively had 
also high VEGF and hsCRP levels. Furthermore a high plaque vulnerability 
score (between 3 and 5) was associated to higher hsCRP and VEGF serum 
levels compared with patients with non-vulnerable plaques. Plaques 
containing a thin fibrous cap were found in patients presenting pre-operative 
neurological symptoms (TIA, Stroke, AF), strengthening the relation 
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between TFC and risk of embolization of vulnerable plaque with a fibrous 
cap thinner. Interestingly, there was an inverse linear correlation between 
VEGF, PAPP-A mRNA, triglycerides serum levels and fibrous cap thickness 
of the carotid plaque: the fibrous cap was thinner in patients with higher level 
of these 3 markers. Patients having higher HDL levels had a thicker fibrous 
cap; as said before HDL removes excess cholesterol from walls’ arteries, thus 
reducing the availability of LDL up-take inside the lesions. As shown in 
previous studies, HDL appears to a have a protective effect against the risk of 
plaque rupture and embolization (Assmann et al., 2004). 
 
PAPP-A level: a technical issue 
PAPP-A mRNA level expression in blood was more sensitive than 
serological analysis of PAPP-A protein expression level; mRNA increased 
up to 30 times in certain patients while PAPP-A serum level increased 
maximum 3 times. Increased mRNA expression level correlated with 
serological SAA levels (and active PAPP-A), glycaemia levels and with the 
area of the filter covered by debris. We repeated the same ELISA assay twice 
to evaluate active PAPP-A concentration in the serum but with scarce results. 
PAPP-A concentrations were extremely low and the concentration curve was 
flat. Many studies evaluating serological PAPP-A obtained opposite results; 
in some cases PAPP-A was correlated to cardiovascular disease (Qin et al., 
2002) and in others there was not any correlation with the disease 
Dominguez-Rodriguez et al., 2005). mRNA PAPP-A evaluation could be 
more sensitive and precise than the evaluation of protein concentration in the 
serum.   
 
PAPP-A bound to the membrane of cells has got proteolytic activity, 
although internalized PAPP-A has little or no protease activity. In our 
histological analyses we saw that dPAPP-A was found in some macrophages, 
some endothelials’ cells and rare SMCs. 
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Our results correlate with a model proposed by Conover et al., in which 
activated macrophages in developing plaque secrete pro-inflammatory 
cytokines that differentially stimulate ECs and SMCs to express and secrete 
PAPP-A, which can act in an autocrine and paracrine manner to amplify 
atherosclerotic disease progression through its ability to enhance local IGF 
action. (Conover et al., 2008).  
A positive correlation was found between macrophages dPAPP-A positive 
cells in patients with dyslipidemia (not shown). This is concordant with in- 
vitro studies showing that IGF activates LDL cholesterol uptake by 
macrophages suggesting a pro-atherogenic activity. (Renier et al., 2000). 
 
HsCRP and SAA 
hsCRP and SAA are marker of inflammation; both have a standard reference 
range but with a different means. In particular, hsCRP is a recognized marker 
in the prevention of cardiovascular disease. Regarding SAA, the reference 
range refers only to an accumulation of the amyloid proteins but not to an 
increase of the risk of cardiovascular disease. Here we showed a perfect 
linear positive correlation between increased levels of SAA before CAS 
procedure and cerebral lesions occurring during the procedure. Until now 
SAA levels were only correlated to cerebral infarction, it is the first time that 
SAA levels are associated directly with the number and the volume of 
cerebral lesions. Serological SAA may be the etiologic factor for ischemic 
stroke, so efficient treatment of chronic infectious inflammatory processes is 
of utmost importance. Until now we considered hsCRP as the best marker for 
cardiovascular disease but it is worthy to introduce SAA as a new standard 
pre-operatory blood test in addition to hsCRP.  
The gene for SAA4 is constitutively expressed and its protein product is a 
constituent of normal, non-acute-phase high-density lipoprotein (Urieli–
Shoval, 1998). We observed that SAA4 is not expressed in normal arteries, 
but in carotid lesions SAA4 positivity is very strong (data not shown). This 
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suggests a tissue-specificity of the SAA4 isoforms towards SAA1 and SAA3. 
SAA4 is a specific marker of carotid atheromatous lesions.  
SAA emerged as an interesting histological and serological marker in this 
study. SAA serum levels are also associated to neoangiogensis, particularly 
to the presence of dots vessels. Patients presenting plaques with a high 
neoangiogenesis score and showing dots vessels structure had an increase of 
pre-operative SAA serum levels. SAA serum levels are related to the plaque 
structure as a potential marker of plaque vulnerability 
Plaque containing calcified nodules showed basal serum levels of SAA and 
hsCRP; in these complications, histological inflammation and 
neoangiogenesis are almost absent.  
 
Circulating molecular markers: peripheral model to study local damage? 
Higher expression level of NSE and PAPP-A mRNA post procedural were 
correlated to the increase of circulating inflammation markers (hsCRP and 
SAA) and also to the presence of a thinner fibrous cap (TFC). However NSE 
was neither sensitive nor specific in predicting patients with cerebral lesions. 
The major concentrations of NSE are found in the gray matter (composed of 
a majority of neurons) opposite to the white matter as the pyramidal tract and 
corpus callosum that contain the lowest concentration of NSE. NSE is 
therefore a specific marker for lesions occurring in the gray matter. So NSE 
is not specific for the cerebral white matter, but injuries can occur with the 
same probabilities in the gray matter. If cerebral lesions are concentrated in 
the gray matter NSE expression levels will not be significantly affected. This 
data is consistent with precedent studies that have shown the inefficacy of 
NSE as a cerebral lesions’ marker (Fridriksson et al., 2000). The optimum 
resides in proteins expressed in both areas and overall having a molecular 
structure able to cross the blood brain barrier. NSE mRNA expression level 
is correlated with inflammation levels of hsCRP and SAA pre-procedural. 
We thought that this increase is due to leucocytes infiltration into cerebral 
brain lesions (Glatt et al. 2005; Sullivan et al. 2006) and subsequent release 
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of leucocytes in the peripheral blood thus correlating with hsCRP and SAA 
levels. So NSE levels reflect a general state of inflammation that might be 
caused by brain injury but is not proportionally related to the number and 
volume of lesions. The same hypothesis is related to PAPP-A mRNA 
expression levels; blood mRNA expression of PAPP-A might increase 
because leucocytes infiltrate into the atheromateous lesion and are 
subsequently released into the blood. Thus reflecting the local concentration 
of mRNA PAPP-A in atheromateous plaques. Peripheral circulating 
leucocytes are very promising for the analysis of local concentration in 
tissue. This is concordant with previous studies on circulating mRNA as 
tumour marker (Somma et al 1999, D’Alessandro et al., 2008).  
 
Neoangiogenesis and atherosclerosis development 
A “classic” model describes the first-order Vaso Vasorum (VV) to derive 
from major arteries, running longitudinally along the vessel wall. Second-
order VV originating from first-order VV form a plexus around the 
adventitia and the vascular media. These two orders of VV are different in 
size, function and anatomic sites: the VV <50 mm in diameter that we 
described in this study are likely to represent the second-order VV 
(described in animal models as vessels of 60-70 mm in size), while the 
vessels ≥100 mm should represent the first-order VV (more than 150 mm in 
pig coronary arteries) (Kwon et al., 1998; Moreno et al., 2006; Ritman et 
al., 2007; Mulligan-Kehoe et al., 2010). We have chosen to maintain a 
“grey zone”, from 50 to 100 mm in diameter, because it is sometimes 
difficult to evaluate vascular size, due to cut effects which can induce an 
overestimation of capillary diameter. The results we obtained seem to 
support this view, as the 50-100 mm VV showed intermediate IHC 
expressions, but were more similar to the <50 mm VV group. 
Nestin is a progenitor cell and angiogenic marker, also involved in early 
development steps in embryogenesis (Wagner et al., 2006; Green et al., 
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2009) and WT1, a transcription factor of Nestin, which acts also as a critical 
regulator of organogenesis (Hohenstein et al., 2006). Here we saw that both 
proteins are expressed in adult arteries as well. The variability among VV is 
reflected by the different expression of Nestin and WT1 that we found 
analysing the adventitia of healthy arteries. Indeed a more pronounced 
expression of Nestin and WT1 was found in VV <50 mm in diameter 
(which show more than 90% of positive cells) rather than VV >100 mm in 
diameter (which are often negative and, when positive, show a mean of 
60% of positive cells). Furthermore, those small-sized VV positive for 
Nestin and WT1 are recognizable in areas (that we called “hot spots”), 
characterized by several small-sized VV, arteriolar in morphology, often 
together with peripheral nervous structures (identifiable with the nerva 
vasorum). Due to their location (deeper layer of adventitia, relatively far 
from media) and morphology (“network” of small vessels with nervous 
structures), we can hypothesize that the “hot spots” may represent points 
where second-order VV originate from a branching of first-order VV (see 
Fig. 13). The “hot spot” could therefore represent a valid model for the 
vasculogenic niche, i.e. a specific domain with a specific architecture and a 
specific location, containing several Nestin- and WT1-positive vascular 
structures. 
As previously said, Nestin gene transcription is regulated by WT1 (Wagner 
et al., 2006; Pelizzoli et al., 2008). Our results show that Nestin and WT1 
are expressed in the same cell population in healthy arteries. Interestingly, 
WT1 is both expressed in the cytoplasm and in the nucleus. For a long time 
the presence of WT1 in the cytoplasm was attributed to an antibody-
staining artefact (Hohenstein et al., 2006) and there was no evidence of 
WT1 cytoplasmic expression at IHC. Our finding correlates with recent 
studies showing the presence of WT1 in the cytoplasm. The cytoplasmic 
isoform WT1 (+KTS) has a high affinity for RNA, while the nuclear 
isoform (–KTS) binds DNA. These and other observations have led to the 
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proposal that the –KTS form of WT1 acts as a transcriptional regulator, 
while the +KTS form, in the cytoplasm, plays a role in RNA processing 
(Green et al., 2009). The cytoplasmic colocalization of WT1 and Nestin 
strengthens the role of WT1 as a post-transcriptional activator of Nestin 
protein. It would be interesting to compare WT1 sub-cellular localization in 
normal arteries versus pathological arteries to assess a correlation with 
neovascularization during atherogenesis. Indeed recent studies showed how 
an increase of WT1 in the cytoplasm is associated with different processes 
in cell differentiation (Wagner et al., 2008). In our series WT1 was mainly 
cytoplasmic in the larger vessels, while nuclear expression increased in the 
smaller vessels (“second-order” VV). 
We want to point out that in atherosclerotic plaque the count of positive cells 
was performed only for the region of interest. So the increase in the number 
of positive cells or field between healthy and atherosclerotic plaque is not 
relevant in this analysis.  
As in healthy arteries, atheromatous lesion vessels still expressed Nestin as 
well as CD34. In healthy arteries 90.0% of vessels Nest+ are WT+ but in 
atheromatous lesion only 55.9% of Nest+ are WT+. Moreover “dots” vessels’ 
structure in atheromatous plaque strongly express Nestin and CD34 but 
weakly express WT1 (phenotypes CD34+/NEST+). Nestin expression is not 
anymore only depending on WT1; within the atherosclerotic lesions Nestin 
expression is driven by the activation of additional transcriptional factors. 
WT1 is well studied as a tumour suppressor and recently the implication of 
WT1 in the vascular response to myocardial ischaemia and its oncogenic 
potential was seen as a promoter of tumour angiogenesis (Scholz et al., 
2009). Angiogenesis is regulated by the balance of proangiogenic 
VEGF(165) and antiangiogenic VEGF(165)b splice isoforms. Mutations in 
WT1 suppress antiangiogenic VEGF(165)b and cause abnormal 
gonadogenesis, renal failure, and Wilms' tumors (Amin et al., 2011). We 
suggest that, as in tumour, a mutation of WT1 could lead to a loss of 
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repression (or function) on angiogenesis, thus to an abnormal 
neovascularisation.  
EPCs, contiguous to the VV in the adventitia of healthy arteries (hot spot) 
have a Nest+/WT+ phenotype. In the atheromatous lesions, under a 
biochemical or mechanical stimulus, EPCs proliferate in the media and 
promote neovascularization of the media leading to the formation of new 
vessels Nestin+/WT-. Additionally new vessels can also sprout from the 
endothelial cells from II order vessels advancing in the media. According to 
some authors, the main source for angiogenesis in diseased arteries is the 
proliferation of VV, and in particular second-order VV located in adventitia 
(Kwon et al., 1998; Mulligan-Kehoe et al., 2010). However the 
Nestin+/WT- phenotype suggests the formation of vascular structures from 
circulating or tissue-resident endothelial stem cells, which proliferate into 
“de novo” endothelial cells in the media.  
In both cases, our “hot spots” represent the main manifestation of this 
proliferative potential: Nestin positivity is to be considered as a 
characteristic of a “young” endothelium, still progenitor committed, and not 
as an expression of real stem cell potential. Furthermore, the nuclear 
localization of WT1 could be associated with an increasing transcriptional 
activity in the “hot spots”. These committed progenitor cells play a key role 
in neovascularization during atherogenesis. Patients with elevated SAA 
serological levels presented plaque with this particular structure named 
vessels “dots”. The presence of dots in atherosclerotic plaque is associated 
to an active neovascularization process.  
Plaque remodelling has been the target of medical therapies, such as statins, 
aiming at the possibility of transforming an unstable plaque into a more 
stable plaque, reducing the cerebrovascular risk (Watanabe et al., 2005). 
The formation of new blood vessels around an atherosclerotic lesion plays a 
major role in plaque rupture, and the use of antiangiogenic drugs stabilizing 
plaques could prevent the arising of cardiovascular events. 
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Calcified plaques 
A subgroup of patients presenting calcified nodules was identified among 
atheromateous lesions. We saw that plaque presenting calcified nodules 
correlates with different clinical, serological and histological features 
compared to atheromateous plaque without nodules. They are not associated 
to the neoangiogensis and inflammation process. Serum levels of hsCRP and 
SAA are not related to plaque vulnerability or any clinical symptoms in 
plaque with calcified nodules. Previous studies of our group showed the 
presence of mesenchymal vascular wall cells resident in the healthy arteries 
having adipogenic, chondrogenic, leiomyogenic and osteogenic potential 
(Pasquinelli et al., 2010). Moreover in PAOD diabetics patients data 
suggested that resident endothelials progenitors cells resident near Vasa 
Vasorum under injury cause a dysfunction of angiogenesis in the media. 
(Orrico et al, 2012). 
 
 
 
 
 
Observations hsCRP SAA VEGF mRNA NSE 
Serum values  >5mg/l >10mg/l >500pg/ml 
SEM and OM 
analysis of filters 
Increase of the 
debris 
accumulation 
Increase of the 
debris 
accumulation 
Increase of the 
debris 
accumulation 
Cerebral damage 
after CAS  
Increased n° and 
Volume of cerebral 
lesions 
Increased n° and 
Volume of 
cerebral lesions 
 
In patients 
submitted to 
CAS; levels 
increased 32%. 
mRNA NSE 
increased with 
inflammatory 
proteins levels 
Type of plaque: 
GSM 
CEA analysis 
 
Dishomogeneous 
High vulnerability 
score (3-5) 
 
Dishomogeneous 
High 
vulnerability 
score (3-5) 
 
Thinner fibrous 
cap 
vulnerability 
score (3-5) 
 
Thinner fibrous 
cap 
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CEUS analysis 
(high dB-E 
signal) 
High vulnerability 
score (4-5) and 
inflammation score 
CT scans+: 
Ipsilateral 
ischemic lesion 
preoperative 
Higher vessel 
density 
Fibrous cap 
<200um 
Thinner fibrous 
cap 
Increase serum levels of VEGF, NSE, 
PAPP-A serum levels increase. 
Neurological symptoms. 
“dots” vessels 
 
High neoangiogensis score, 
CD34+/Nest+/WT- 
Increase serum levels of SAA, 
dPAPP-A+ macrophages 
 
Table 1: Main findings of this study 
 
Main findings of this study: 
The table 1 above summarizes our main findings 
- First study to show that pre-procedural serum levels of SAA are directly 
related to the number of cerebral lesions post stenting.  
- SAA4 protein isoform appears to be a tissue specific histological marker 
of atheromatous lesions; a quantitative analysis is necessary to prove the 
statistical significance. 
- Circulating protein and mRNA reflect the local structure of the 
atheromateous plaques. 
- The presence of a thin fibrous cap is associated to neurological symptoms 
and to circulating protein levels  
- Atherosclerotic plaque vessels showed a different phenotype compared to 
healthy plaque Nest+/WT- 
- Nestin driven neoangiogensis in atheromateous palque is activated by an 
alternative transcriptional factor alternative to WT1 
 
Based on this findings two questions arise: 
- Are committed progenitor cells located in adventizia responsible for 
abnormal neovascularization during atherogenesis? 
- What event triggers the new phenotype of neovessels in atheromateous 
plaques? 
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Previous data of our group showed that osteoprogenitors cells are contiguous 
to Vasa Vasorum where they are inactive and under an unknown stimulus, 
cells migrate in the media producing bone matrix (Pacilli 2011). This 
mechanism is concordant to our hypothesis on neovessels’ formation during 
atherogenesis. Our ongoing research is now oriented versus the mechanisms 
that trigger the bone formation and the neovessels’ formation. Understanding 
the unknown early stages of atherogenesis is of fundamental importance for 
the development of a drug that is targeted to inhibit the possible progenitors’ 
cells involved.  
 
Conclusion 
This study identifies patients at major risk of embolization and cerebral 
lesions. Ultrastructural analysis pointed out how debris dislocates from the 
carotid plaque during the procedure and passes through the pores of the filter 
leading to the formation of cerebral lesions. These data show that the stenting 
procedure is not indicated in patients with hsCRP, SAA and VEGF higher 
than the threshold values. CEUS with dB-E can be used as a marker for 
neovascularization and vulnerable plaque.  
 
Limits of the study 
 
This study included a limited amount of patients. Carotid plaque analysis is 
limited to patients who undergo vascular surgery, which limits the domain of 
patients suitable for risk assessment. Plaque analysis takes place at one point 
in time, while it is known that atherosclerotic plaque composition changes 
over time. We continue now to perform analysis on the area near the 
atheromateous lesion.  
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